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i 
ABSTRACT 
 
Most oral cancers lack early symptoms that would prompt a patient to seek 
diagnosis; hence at presentation more than 60% of patients are diagnosed 
with stage III or IV advanced disease. Survival rates and morbidity are 
dramatically improved if the disease is treated at an early stage, preferably 
asymptomatic in stage one. Therefore, early detection of oral cancer and oral 
potentially malignant lesions in the asymptomatic phase via an oral cancer 
screening examination is important. 
 
The core objective of this thesis is to determine whether asymptomatic 
diagnosis of oral cancer at an early stage of disease is achievable in 
Australia. We achieve this by evaluating the awareness of, and attitudes 
toward, oral cancer and opportunistic screening held by recently-diagnosed 
oral cancer patients, experienced general medical practitioners, and recently-
graduated medical students.  
 
Two studies are detailed herein. The first involved recruitment of a cohort of 
103 Australian patients diagnosed with pathologically verified oral cancer 
(excluding lip) through the Royal Brisbane and Women’s Hospital (RBWH) 
Head and Neck Clinic to complete a 36-part questionnaire to address the 
above aims. The second study involved a questionnaire that was mailed to 
553 General Medical Practitioners (GMPs) randomly selected from a 
database developed from GMPs working in locations expected to refer 
suspected oral cancer patients to the RBWH Head and Neck Clinic. A similar 
questionnaire was designed to collect data from a sample of 151 Graduated 
Medical Students (GMSs) commencing work as intern medical officers at the 
RBWH and the Princess Alexandra Hospital (PAH) in Brisbane, Australia.  
 
From these studies we found that participants with oral cancer had poor 
awareness of oral cancer and poor knowledge of risk factors prior to 
diagnosis. Nearly all were over 40 years of age and most consumed tobacco 
or alcohol or both, suggesting a target population for opportunistic screening 
in the primary healthcare setting. Patient, professional, and total diagnostic 
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delay were better than in many other countries. In the asymptomatic phase 
before diagnosis, participants with oral cancer were more likely to visit a GMP 
over a General Dental Practitioner (GDP), and likely to do so multiple times 
each year, identifying significant opportunities for GMPs to perform 
opportunistic oral cancer screening.  
 
We also found that Australian GMPs and GMSs have an inadequate level of 
knowledge of oral cancer, OPMLs, risk factors, and inadequate skill in 
performing opportunistic oral cancer screening examinations. At the present 
level of knowledge and confidence, it would be unlikely for a GMP to conduct 
a thorough visual and tactile oral cancer screening examination even if a high-
risk individual presented to his or her clinic. Only 7% of participants with oral 
cancer were diagnosed in the asymptomatic phase, and all were diagnosed 
by health practitioners with a dental qualification. 
 
We conclude that asymptomatic diagnosis of oral cancer at an early stage of 
disease is achievable in the primary medical healthcare setting in Australia via 
opportunistic oral cancer screening. Initiating a consultation with a GMP or 
GDP for an oral cancer screening examination would require a patient to have 
an improved awareness of oral cancer and knowledge of his or her personal 
risk factors for developing it. To increase opportunistic oral cancer screening 
activity from Australian GMPs, interventions need to ensure that GMPs and 
GMSs reach competence in risk factors for oral cancer, identifying high-risk 
populations, diagnostic confidence, and skill in performing the nine-step visual 
and tactile opportunistic oral cancer screening examination.  
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CHAPTER ONE: INTRODUCTION 
 
Oral cancer (OC) refers to all aggressive neoplasms that affect the external lip, oral cavity, 
and oropharynx; however, the predominant type is oral squamous cell carcinoma (OSCC) 
and can affect all tissues of epithelial origin.1, 2 Worldwide, oral cancer has one of the 
highest mortality rates among all malignancies.3 It is recognized as the sixth most common 
cancer, and 270,000 new cases are expected each year.1, 3, 4 There is significant disparity 
in geographical incidence across the world, suggesting geographical differences in risk 
factors, most of which have been identified in other epidemiological studies.5-7 In South 
Asia and the Indian Subcontinent oral cancer accounts for almost one third of all 
malignancies, in contrast to the Western world, where it is comparatively uncommon and 
accounts for only 2-5% of all malignancies.5, 8 India, Sri Lanka, and Pakistan have the 
highest levels of the disease, and it is the most common cancer for men in these countries 
and accounts for up to 30% of all new cases of cancer compared, to just 3% in the United 
Kingdom (UK) and 6% in France.9 The prevalence of oral cancers is high in countries of 
South Asia and the Indian Subcontinent, where distinct cultural practices, such as betel nut 
chewing, and varying patterns of tobacco and alcohol use are important risk factors that 
predispose people to cancer of the oral cavity.10  
 
To add an Australian context, between 1992 and 2008, 60826 cases of lip, oral cavity, and 
oropharyngeal cancer were diagnosed and registered on the Australian Cancer Database 
with the Australian Institute of Health and Welfare (AIHW).11 These cases represented 
2.9% of the total cancer burden in Australia and caused 1.6% of all cancer deaths, which 
is very similar to the UK population.9, 11 The incidence rate of all sites was between 10 and 
14 per 100,000 population for both sexes combined.11 Males accounted for 71% of all 
cases diagnosed compared to 29% for females.11 Over the 27-year period of Australian 
data analysed by Farah et al. (2014), there was no significant change in incidence, and 
overall mortality associated with oral cancers remained stable despite advances in imaging 
and treatment modalities, however cancers of the tongue and oropharynx showed an 
increasing trend over time.11 
 
Overall, the five-year survival rate for oral cancer is approximately 50% for all anatomical 
sites and stages.11 The most important prognostic marker for oral cancer remains tumour 
stage at diagnosis.6, 12 Unfortunately, most oral cancers lack early symptoms, and hence 
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more than 60% of patients present with advanced disease, either stage III or IV oral 
cancer.13, 14 The reported five-year survival rate of stage III or IV oral cancer ranges 
between 15% and 55%.15-18 In contrast, oral cancers diagnosed at a smaller size and 
without lymph node involvement in stage I or II report a five-year survival rate ranging 
between 66% and 85%.11, 15, 19 A recent analysis of 22,204 pathologically verified oral 
cancers followed up over ten years concluded that early diagnosis and intervention before 
stage II can significantly improve life expectancy and decrease expected years of life lost 
to oral cancer.18 This is ideally when the patient is likely asymptomatic with a tumour less 
than 2cm in diameter and with less than 4mm of invasion.18, 20 Therefore, early detection of 
malignant lesions and oral potentially malignant lesions (OPMLs) is an important goal for 
reducing morbidity and mortality.14, 15, 21, 22 
 
The Cochrane collaboration and other expert consortia agree that whilst population-based 
annual or semi-annual screening for oral cancer is not cost-effective, targeting high-risk 
populations to be opportunistically screened using a visual and tactile examination should 
be encouraged in the primary care setting.23-26 Opportunistic oral cancer screening by 
general medical practitioners (GMPs) and general dental practitioners (GDPs) should 
remain an integral part of the routine daily work of these groups, and particular attention 
should be paid to high-risk individuals.27 In Australia the most significant risk factors for the 
development of oral cancer are likely to be increased age and tobacco and alcohol 
consumption.28, 29 Prevention and early-stage diagnosis may be important for oral cancers 
because these known risk factors enable identification of high-risk populations, and 
identifying oral cancers and oral potentially malignant lesions (OPMLs) is relatively easy 
via a simple visual and tactile oral cancer screening examination. 
 
Recent research suggests that GDPs in Australia are actively screening the oral mucosa 
for most patients as part of their routine daily work, but falls short of determining whether 
the GDPs perform all nine steps of the visual and tactile oral cancer screening examination 
suggested by the World Health Organisation (WHO) and National Institute of Dental and 
Craniofacial Research (NIDCR).27, 30, 31 There have been no investigations into the 
awareness of, knowledge of, and attitudes toward opportunistic oral cancer screening in 
the Australian GMP population. Similarly, there is no study that investigates these same 
attributes in graduated medical students (GMSs) as they exit medical school and enter the 
workforce. Chapter 4 of this thesis establishes these two Australian datasets via a survey 
of GMS and practicing GMPs in Brisbane. Chapter 3 investigates a cohort of Australian 
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patients with pathologically confirmed oral cancer attending the Head and Neck Clinic at 
the RBWH in Brisbane. These patients are studied regarding patient awareness, 
knowledge of risk factors, actual risk factors, patient delay, professional delay, diagnostic 
delay, and access to health practitioners in the Australian health system in the 
asymptomatic phase. Prior research has focused on review of patient and professional 
delay, but importantly this research precedes the patient delay phase and focuses on the 
asymptomatic phase wherein the oral cancer may be present and detected at an earlier 
stage of disease.32 A key aim is to identify missed opportunities for early diagnosis of 
malignant lesions or OPMLs by investigating patient interactions with GMPs and GDPs in 
the asymptomatic phase. 
 
The purpose of these research endeavours is to establish three Australian datasets that 
will provide valuable insights and lead to development of public health messages and 
policy, development of educational and training interventions at the undergraduate and 
postgraduate level, and ultimately to increased rates of visual and tactile opportunistic oral 
cancer screening in the primary medical healthcare setting. Asymptomatic diagnosis of 
oral cancer in the early stages of the disease should be achievable in Australia and is key 
to reducing mortality and morbidity caused by oral cancer. 
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CHAPTER TWO: LITERATURE REVIEW 
 
2.1 Oral Potentially Malignant Lesions and Oral Epithelial Dysplasia 
Globally, over 90% of oral cancers are OSCC, a malignancy that has a high tendency to 
metastasize to regional lymph nodes and occurs most often in individuals over 40 years of 
age.1, 4 Tumour stage at diagnosis remains the most important prognostic marker for oral 
cancer.19, 33 Therefore, there is a need for early diagnosis of oral cancer, ideally at the 
premalignant or potentially malignant stage, in order to reduce morbidity and mortality.14, 15, 
21, 25, 34 Oral potentially malignant lesions (OPMLs) is the collective term for the wide range 
of clinical presentations of oral lesions that may harbour oral epithelial dysplasia (OED). 
Clinically, OPMLs can appear as leukoplakia, erythroplakia, or erythro-leukoplakia 
(speckled erythroplakia).22 Although various other factors, such as smoking history, patient 
age and gender, and lesion size and location may contribute to the suspicion of malignant 
potential, the clinical appearance is often the primary driving factor toward the decision to 
biopsy or offer intervention.35 Leukoplakias, the most common OPMLs, show a low rate of 
malignant progression (4-18%) irrespective of the histopathologic diagnosis of mild, 
moderate, or severe dysplasia.36 In contrast, erythroplakias and erythro-leukoplakias have 
been shown to have a much higher risk of malignant transformation (14-50%).37 We can 
confidently state that lesions exhibiting redness or a non-homogenous texture are strongly 
associated with OED and should be considered for biopsy at presentation.38-40 
Homogenous lesions that presented on the tongue or floor of the mouth are also 
significantly more likely to be dysplastic, and more so if tobacco consumption is part of the 
presentation.41, 42 Unfortunately, these clinical features at presentation may estimate the 
rate of OED in OPMLs but there is no way of differentiating OPMLs into dysplastic and 
non-dysplastic on clinical findings alone, because OED can manifest clinically in any 
number of presentations.42-44 
 
OED is the histopathologic diagnosis that describes this precancerous stage, and it is 
characterized by a range of cellular and morphologic tissue changes which are similar to 
those of SCC but are restricted to epithelial cells and remain non-invasive.1 The most 
recently accepted histological classification developed by the WHO divides OED into mild, 
moderate, and severe dysplasia (otherwise known as carcinoma in situ).1  However, unlike 
the stepwise progression in severity of cervical pre-cancerous lesions, there is no step-
wise pattern of progression in oral cancer.   
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A recent retrospective study of 368 patients showed that for all oral sites and all WHO 
dysplasia grades, the annual malignant transformation rate was 1% and the annual 
progression to higher grade of dysplasia was 3%.41 In a comparable population the annual 
malignant transformation rate was 1.8% and 5.6% for moderate and severe dysplasia, 
respectively, indicating that histological grading was a risk factor for transformation to 
malignancy.45 In contrast, other studies showed no association between transformation 
rates and grading of dysplasia.44, 46 The use of histopathology for the diagnosis and 
categorization of OED has long been considered imprecise, with poor inter- and intra-
observer agreement and low levels of reproducibility.47, 48 Therefore, the usefulness of 
grading OED has been contested in the literature, and there is currently no consensus 
regarding risk of malignant transformation based on histopathologic grading of the OED.49 
 
The most current systematic review of the literature regarding treatment and follow-up of 
oral dysplasia suggests that removing dysplasia reduces but does not eliminate the risk of 
OSCC formation.50 However, given the lack of consistent correlation of OED 
histopathologic grading with transformation to malignancy, it appears only prudent to 
perform a more definitive treatment of OPMLs exhibiting any grade of dysplasia, rather 
than to limit treatment to severe cases. 41 This is an unfortunate outcome of the poor 
predictive value of the WHO OED grading classification, which cannot be used reliably as 
a guide for treatment decision-making.41 Although complete excision of OED may be 
considered by some as overtreatment, in contrast, the ongoing surveillance of retained 
OED even with regular review is increasing risk of harm to the patient by malignant 
transformation over time and should be regarded as an ineffective treatment option.42, 44, 46, 
51 In summary, definitive treatment of all OED is recommended. 
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2.2 Risk Factors for Oral Cancer 
Oral cancer is a multifactorial disease and the pathogenesis is equally complex. Oral 
cavity carcinomas are predominantly caused by chemical carcinogens, although evidence 
implicating infectious factors (e.g. human papilloma viruses) and physical stimuli (e.g. 
recurrent trauma or chronic inflammation) in some carcinomas continues to grow.52, 53 The 
most prominent modifiable risk factors are lifestyle factors, including tobacco and tobacco 
products, alcohol, betel quid chewing, and poor diet, while the non-modifiable risk factors 
are increasing age (>40 years) and sex (male > female).15, 21, 54 
 
2.2.1 Tobacco 
A considerable body of evidence supports a strong association between oral cancer and 
tobacco use.5 The use of smokeless tobacco has been show to increase the risk of 
developing oral cancer by up to four times, but smoking tobacco is far worse.5 Smoking 
tobacco increases the risk of developing oral cancer from three to seventeen times that of 
a non-smoker.21, 55-58 The data also suggest that a lifetime dosage relationship exists. 
Smokers of greater than thirty pack-years show an odds ratio of 2.9 (1.8 ~ 4.5 95% CI) 
compared to those with greater than forty pack-years with an odds ratio of 8.46 (6.22 ~ 
11.50 95%CI)  and those with a greater than sixty pack-year history an odds ratio of 10.1 
(6.1 ~ 16.7 95%CI). 56-58 In addition, approximately 80% of oral cancer patients are 
smokers and thus are a target population for screening activities.59, 60 
 
2.2.2 Alcohol 
Alcohol consumption is often cited as a known risk factor for oral cancer.61-63 In 
epidemiological studies controlled for smoking, a moderate to heavy alcohol consumption 
has been shown to increase the risk of developing oral cancer from three to nine times that 
of abstainers.59, 60, 64, 65 Whilst the definition of moderate to heavy alcohol consumption 
varies from study to study, the conclusion of the majority of the literature is that higher 
lifetime alcohol consumption is correlated with increased risk of oral cancer. There is also 
significant evidence to suggest a synergistic effect between alcohol and tobacco 
consumption in the development of oral cancer.58, 59 
 
2.2.3 Areca Nut Consumption 
The areca nut is carcinogenic to humans and has been declared as such by the 
International Agency for Research on Cancer.66-71 It is often consumed during betel quid 
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chewing and is more commonly referred to as betel nut chewing, which is a misnomer 
given the nut component of the betel quid is the nut of the areca palm. Betel quid is 
prepared by adding different ingredients such as betel fruit, betel leaf, lime juice, tobacco, 
and other flavours to the betel nut according to local traditions that vary across Asia and 
the subcontinent.72-74 Whilst areca nut consumption and betel quid chewing is not 
prominent in the Australian population, it is practised by 600 million people worldwide, and 
is the fourth most commonly used drug in the world, after alcohol, tobacco, and caffeine.66 
Gene expression is distorted by hypermethylation with alkaloids from the betel nut, which 
may block tumour suppressor genes such as p14, p15, p16, and p53.75-77 People who 
chew areca nut, but do not smoke or consume alcohol, have an odds ratio of 10.97 (3.22 ~ 
37.34 95%CI) for developing oral cancer.58, 78 There is also significant epidemiological 
evidence of a synergistic effect between tobacco, alcohol, and areca nut consumption in 
the development of oral cancer.63, 79, 80 
 
2.2.4 Human Papilloma Virus (HPV) 
The evidence for the role of HPV as an aetiologic agent in oral cancer has grown rapidly. 
Two recent meta-analyses found HPV to be an independent risk factor for oral cancer, but 
predominantly in the anatomical subset of oropharyngeal cancers.81, 82 HPV infections in 
the progression of head and neck cancer (HNC) have been consistently noted in 25% of 
cases.81, 83, 84 Over 100 different types of HPV exist; however, fewer than twenty are 
thought to have oncogenic potential.85 HPV-16 is the most common genotype found in oral 
cavity and oropharyngeal cancer.86 The E6 and E7 proteins produced by HPV-infected 
cells are thought to dysregulate the function of two oncosuppressors, p53 and pRb, 
resulting in uncontrolled DNA replication and impairment of apoptosis.87 The combined 
effects of these leads to an increased tendency toward carcinogenic change. Studies 
suggest that HPV is a sexually transmitted infection.88 Rates of survival and local 
recurrence are much better in HPV-positive oral cancer.89, 90 Individuals who also smoke 
are at high risk of developing HPV-16 positive HNC, and the prevalence of HPV-related 
HNC is increasing; this trend may be attributable to changes in sexual behaviours, 
particularly oral sex.57, 91, 92 
 
2.2.5 Poor Diet and Nutritional Deficiencies 
Poor diet, or a diet lacking fresh fruit and vegetables, has emerged as a significant risk 
factor for HNC, independent of tobacco, alcohol, betel nut consumption, and HPV.93, 94 As 
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with other carcinomas outside the oral cavity, a diet high in consumption of fruits and 
vegetables appears protective against oral cancer when epidemiologic studies are 
controlled for tobacco and alcohol use.95 Further investigation into this phenomenon has 
shown that β-carotene and vitamin A supplementation resulted in substantial regression of 
some OPMLs.96, 97 Increased consumption of green leafy vegetables and non-starchy 
tubers such as carrots reduces the risk of oropharyngeal cancer.98 Iron deficiency anaemia 
in animal and human studies of the oral epithelium is often atrophic, in addition to showing 
rapid epithelial turnover.99, 100 One hypothesis for this as a risk factor for oral cancer is that 
iron deficiency may increase one's susceptibility to chemical carcinogens from the thin, 
atrophic, more permeable epithelium, and also from the high number of vulnerable dividing 
cells due to increased turnover.100 The effect of individual food components and trace 
elements on carcinogenesis remains unclear.101 
 
2.2.6 Ultraviolet (UV) Radiation  
UV irradiation is the main cause of lip cancer, which is responsible for 30% of all OSCC.102 
A high incidence of lip cancer has been reported among Caucasians and is approximately 
three times higher in males than females, which may be due to more outdoor occupations, 
UV exposure, and tobacco exposure amongst men.103, 104 
 
2.2.7 Age 
There is no doubt that increasing age is a significant risk factor for developing oral cancer. 
In Europe, 98% of all head and neck cancer patients were more than 40 years old.105 
Similarly, in Australia it is rare to diagnose oral cancer (excluding lip) under the age of 40 
years.106  
 
2.2.8 Sex 
Overall, incidence and mortality rates are higher for males than females worldwide. In 
Australia over the 27-year period between 1982 and 2008, 71% of cases were diagnosed 
in males and 29% in females.11 This may relate to higher lifetime consumption of alcohol 
and tobacco. The incidence trend among females is beginning to increase at higher rates 
than in the past, and again it is theorized that females collectively may be consuming 
larger amounts of alcohol and tobacco than before.107 
 
2.2.9 Socio-economic Status 
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Oral cancer is seen more often in people from lower socio-economic groups and those 
living in deprived areas.54 Individuals with lower occupational status or social class, lower 
education level, or lower incomes, and those in manual labour roles, have a greater risk of 
developing oral cancer independent of lifestyle habits such as tobacco and alcohol 
consumption.108, 109 Hypothesized explanations for these socio-economic factors are 
plentiful and include limited access to healthcare and health information, exposure to 
harmful physical environments or agents, and stresses caused by job insecurity or 
unemployment.109  
 
2.2.10 Controversial Risk Factors with Limited Evidence 
2.2.10.1 Oral Hygiene and Chronic Inflammation 
Although poor oral hygiene and poor dentition (faulty restorations, sharp teeth, and ill-
fitting dentures) have been implicated in a few epidemiological studies, it is not clear 
whether confounding by tobacco and alcohol have been addressed in these studies.54, 110, 
111 Periodontal disease has been correlated with increased risk of oral cancer.112 It is 
argued that chronic infection from periodontal disease results in low-grade inflammation 
and oxidative stress, which may contribute to carcinogenesis.112 A recent case-control 
study from Japan found that frequent tooth brushing could reduce the risk of cancer of the 
upper aerodigestive tract, especially in the high-risk group of heavy tobacco and alcohol 
consumers.113 Several oral bacteria also metabolise alcohol to acetaldehyde, a known 
carcinogen.114 Candida albicans can also efficiently convert alcohol to the carcinogenic 
acetaldehyde, similarly to several bacteria in the oral flora.62, 114 Fungal infections, most 
commonly secondary to Candida albicans, may invade the oral epithelium and be involved 
in producing dysplastic change.62, 114 Evidence suggests that in addition to the 
inflammatory response, nitrosamines produced by the fungus may activate proto-
oncogenes.114 
 
2.2.10.2 Ethnicity 
There is much discussion regarding the susceptibility to oral cancer based on ethnicity and 
race, as oral cancer incidence rates vary considerably across different groups in the 
world.4 For example, one study of African-American males showed a 15% higher 
incidence than in white American males.115 Another highlighted that south Asians have a 
far higher incidence that most other groups in the world.4 Nutritional differences, smoking 
patterns, differences in amounts smoked or alcohol consumed, and the two-way and 
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three-way interaction of betel quid chewing with smoking and alcohol, rather than genetic 
factors, may play a role in these observed variations in populations and high incidence in 
some ethnic and racial groups.54 
 
2.2.10.3 Heredity and Familial Risk  
Recently, genetic factors such as p53 mutations, aberrant expression of epidermal growth 
factor receptor (EGFR) and/or ligands for it, and promoter methylation of human MutL 
homolog1 (hMLH1) have all been correlated with oral cancers.116-118 Although oral cancer 
is in part a genetic disease caused by environmental exposure to carcinogens, there are 
no associations with hereditary cancer syndromes to suggest heredity.54 The relative risk 
of oral cavity cancer was between 1.2% and 3.8% for those who had a family history of 
HNC when compared with those with no such family history.119 Knowledge of heredity and 
genetic factors is increasing, but at present it does little to assist the general medical 
practitioner (GMP) or general dental practitioner (GDP) in performing a risk assessment, 
as the evidence for familial aggregation is limited.54 
 
2.2.10.4 Other Risk Factors 
This literature review does not allow discussion of all risk factors, but it is important to 
mention some others from the literature. High levels of heavy metals, such as nickel (Ni), 
chromium (Cr), and arsenic (As), have been correlated with increased risk for oral cancer 
development.120 Immunosuppression is certainly reported to increase lip cancer following 
kidney transplantation and is significantly related to use of azathioprine and 
cyclosporine.121, 122 Other controversial debated risk factors with limited evidence include 
diabetic immunosuppression, HIV infection and resultant immunosuppression, cannabis 
smoking, Khat (qat) chewing, alcohol containing mouthwash, indoor air pollution, and 
nicotine replacement products.54 
 
2.2.11 Oral Cancer Risk Factors in the Australian Population 
In Australia the most significant risk factors in the development of oral cancer are 
increased age, tobacco use, and alcohol consumption.28, 29 Prevalence data on tobacco 
smoking in Australia shows that the daily smoking rate has fallen from 20% in 2001 to 17% 
in 2007 and again to 15% in 2010.123, 124 In contrast, our indigenous Australians had a 
smoking prevalence of 50% in 2007.125  In 2010, 46% of people aged 12 years and over 
drank alcohol at least weekly.124 It is also widely known that Australia’s consumption of 
alcohol per capita is high by world standards, at approximately 10L/year of pure alcohol 
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among individuals over the age of 15 compared to very high at approximately 15L/year for 
indigenous Australians.126 As a nation Australia is at increased risk for developing OC 
based on this level of alcohol consumption.  
 
Whilst it is rare to diagnose oral cancer (excluding lip) under the age of 40 years in 
Australia, the number of oral cancer cases is increasing in females under 45 years of age 
with no history of no alcohol or tobacco use, and ongoing research has implicated, though 
not proven, the role of HPV in such cases.2, 15, 54, 106 The incidence of male and female 
HPV-related cancers has drastically increased annually in Australia, predominantly in the 
oropharyngeal location.91 As a result, the current National HPV Vaccination Programme 
has included both males and females aged 12 to13 years since 2013 and may have an 
effect on the future incidence of these HPV-related cancers.127 
 
Practising GMPs and GDPs in Australia should be aware of the modifiable and non-
modifiable risk factors discussed above. In the developed world the most significant risk 
factors in the development of oral cancer are increased age, tobacco use, and alcohol 
consumption.28, 29 A recent large international pooled study estimated the population 
attributable risks for tobacco and alcohol use to be 64% (95%CI:45-75%), showing that 
these two risk factors alone are responsible for a large number of cases.28 In summation, 
reasonable populations to place in the higher-risk category for developing oral cancer in 
Australia are those over 40 years of age and those who regularly consume of tobacco 
and/or alcohol. 
 
2.3 Timing of Diagnosis and Prognostic Implications 
2.3.1 Prognostic Markers 
Current markers that have been allocated independent prognostic value include age, 
gender, immunological status, nutritional status, size and location of tumour, stage of 
disease, nodal status, oncogene expression, proliferation markers, and DNA content. Of 
these, tumour stage at diagnosis remains the most important prognostic marker for OSCC. 
6, 12 As stated in the Introduction, most oral cancers lack early symptoms and hence more 
than 60% of patients present in stage III or IV.13, 14, 16, 17 The reported five-year survival rate 
of stage III or IV oral cancer ranges between 15% and 55%.15-18 Survival rates improve 
significantly if the disease is treated at an early stage; hence, early detection of malignant 
lesions and OPMLs is important for reducing morbidity and mortality.14, 15, 21, 22 
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2.3.2 Early Stage Diagnosis 
Early detection of disease is a confusing term that can imply either a small tumour at 
diagnosis or a short time interval since development of the oral cancer, which introduces 
the concept of diagnostic delay.23 An early stage at diagnosis is the aim of early detection 
strategies. To achieve an early stage at diagnosis the tumour should be small, less than 
2cm in diameter, and less than 4mm in invasion depth, and is usually asymptomatic.20 A 
difficulty with small-size tumour diagnosis is that by the time the cancer reaches a 
measurable size, it is possible that lymphatic or metastatic spread has already taken 
place.23 A rational conclusion is that clinicians must be vigilant when monitoring OPMLs for 
malignant changes and opportunistic in their screening of higher-risk asymptomatic 
patients such as tobacco and alcohol consumers over 40 years of age.  
 
For this to be achievable in the Australian population, both GMPs and GDPs must be 
knowledgeable regarding oral pathologies and competent to perform oral cancer screening 
examinations. In addition, patients must be aware of oral cancer and their individual risk 
factors for developing it before increased rates of early diagnosis are likely to be seen in 
Australia.  
 
2.3.3 Diagnostic Delay 
In addition to the challenge of finding and diagnosing these lesions at early stage of 
disease, it is also important to note that a significant body of literature suggests that 
diagnostic delay is also a determinant factor in oral cancer survival.25, 128, 129 Diagnostic 
delay generally refers to the time that elapses from the time the patient first becomes 
aware of symptoms until a definitive diagnosis is made following specialist review.  This is 
commonly divided into patient and professional delay. Patient delay refers to the time that 
elapses from when symptoms begin until the patient first meets with a professional for a 
consultation regarding diagnosis.130 Professional delay is the time that elapses from this 
initial consultation, often in the primary care setting, until a definitive diagnosis is made, 
often after referral to a specialist setting. In Australia this often involves biopsy, awaiting 
results, and referral to a specialised head and neck cancer clinic. The total diagnostic 
delay from the literature review averages 3 to 6 months and is roughly evenly distributed 
between patient and professional delay.23 Whilst there is no Australian dataset on 
diagnostic delay, it is anticipated from anecdotal experience that the total delay is similar in 
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the Australian population, and this is investigated in our research. 
 
Causes of patient delay are related to psychosocial issues, such as perceptions of 
symptoms and illness; behavioural responses; accessibility to health care, including 
financial; and structural and personal barriers such as beliefs, culture, and language.131      
Esmaelbeigi et al. (2014) conducted a case-control study to explore factors that affect total 
diagnostic delay in oral cancer, and showed that out of 206 patients in an Iranian 
population, those with primary-level education had a 70% lower risk of delay compared to 
the illiterate patients (OR = 0.3, 95% CI 0.1–0.7), and the risk was lower again among 
patients with diploma-level education (OR = 0.04, 95% CI 0–0.7) and college level 
education (OR = 0.1, 95% CI 0–0.4).132 The delayed patients were diagnosed at a more 
advanced stage than were the patients without delay (OR = 2.1, 95% CI 1.0–4.4).133 A 
recent study investigating barriers to oral cancer screening among rural African-Americans 
showed three primary patient barriers to screening.133 Lack of knowledge (not knowing 
about oral cancer and not knowing oral cancer symptoms) accounted for 31.8% of all 
barriers mentioned, lack of resources (e.g., lack of money and health insurance) for 
25.0%, and fear (e.g., fear of screening and diagnosis) for 22.9%. Howell et al. (2013) 
placed these barriers within the Theory of Planned Behaviour and concluded that 
interventions aimed at increasing oral cancer screening should focus first on changing 
individual’s attitudes toward screening by increasing knowledge about oral cancer and 
reducing fear.133 
 
Causes of professional delay provide an opportunity for interventions, which may lead to 
increase in opportunistic screening of the higher-risk population. Research has shown that 
lack of knowledge regarding the main locations of oral cancer, low suspicion of oral 
cancer, and low levels of skill and confidence to perform a full head and neck examination 
with appropriate equipment are prevalent in the general medical and dental community to 
varying degrees.131, 134-136 The presence of co-morbidities in patients has also been shown 
to result in clinicians focusing their attention on the existing disorders.137-139 Prescription of 
medicines, such as analgesics, in the primary care setting (OR = 5.3, 95% CI 2.2–12.9), 
history of dental procedure (OR=6.8, 95% CI 1.7–26.9), and history of loose teeth 
increased the risk of delay by four times (OR = 4.0, 95% CI 1.6–9.8) and were associated 
with a higher risk of delay compared to patient who were biopsied from the beginning.132 
Two studies suggest a strong relationship between professional delay and decreased 
survival rates, specifically when professional delay is longer than a month.140, 141 Two 
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further studies reported a significant association between professional delay and the 
tumour stage at diagnosis across a spread of different populations.137, 142 
 
Esmaelbeigi et al. (2014) showed that of out of 206 Iranian patients, 71.4% were 
diagnosed with oral cancer at an advanced stage (III-IV).132 The medians of the patient, 
professional, and total delays were 45, 86, and 140 days, respectively.132 In a systematic 
review by Gomez et al. (2009), total diagnostic delay was associated with a more 
advanced tumour stage at diagnosis and the pooled relative risk (RR) was 1.47 (95% CI: 
1.09–1.99).33 However, in a separate systematic review expanded to include all head and 
neck cancers, no association was found between diagnostic delay in head and neck 
cancers and tumour stage at diagnosis.143 Seoane et al. (2010) further challenged the 
strength of the relationship with a statistical analysis of 83 OSCC cases, which showed 
that when the analysis was adjusted for tumour stage at diagnosis (I-II vs. III-IV), 
proliferative activity became an independent prognostic factor for survival, whereas 
diagnostic delay did not influence survival significantly.144 To complicate the issue further, 
research on professional delay and mortality in tongue cancer is even more paradoxical, 
as less professional delay trends toward worse survival rates, which appears to be an 
unreasonable statistical outcome.140, 145 This paradoxical response whereby diagnostic 
delay, tumour stage, and prognosis are inversely related has also been described in 
breast, cervical, lung, colon, renal, and urethral cancer.146 This suggests that stage at 
diagnosis and survival are affected more by the biology of the tumour (for example, rapid 
growth or poor differentiation) than by diagnostic delay.146 
 
Rather than focusing on delay as a major contributor to tumour stage at diagnosis and 
survival, the focus should be shifted to identifying lesions in the asymptomatic period. An 
overwhelming volume of literature shows that many patients are diagnosed in the 
symptomatic phase, often at an advanced stage (III-IV) of disease. As research on 
diagnostic delay by definition deals with the symptomatic phase, if an early stage 
diagnosis is to be achieved, then future research efforts should focus on improving oral 
cancer screening in the asymptomatic phase through appropriate screening strategies. A 
reasonable conclusion is that, regardless of the body of research focusing on diagnostic 
delay from time of first symptoms, the true clinical aim is to diagnose a lesion in the 
asymptomatic phase as either an OPML, an OED, or a small-size tumour at diagnosis; that 
is, less than 2cm in diameter and less than 4mm in invasion depth.20 
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2.4 Screening Strategies 
The WHO defines screening as the presumptive identification of unrecognised disease or 
defects by means of tests, examinations, or other procedures that can be applied 
rapidly.147 The overall benefit should also outweigh any harm that results from screening. 
In addition, when community resources are used to fund screening, there should be a 
community consensus that the benefits of screening justify the expense.148 
 
In Australia, the Australian Health Minister’s Population Based Screening Framework sets 
out clear guidelines, based on the WHO principles of screening, to define when a disease 
is suitable for population-based screening versus opportunistic case-finding, herein 
referred to as opportunistic screening.78 Based on these guidelines, oral cancer does not 
fulfil the requirements for a population-based screening programme.149 
 
A Cochrane systematic review evaluated screening strategies for reducing oral cancer 
mortality and revealed that there is insufficient evidence to recommend inclusion or 
exclusion of screening for oral cancer using a visual and tactile examination in the general 
population.25, 27 According to the WHO and NIDCR, an oral cancer screening examination 
should include a visual examination of the face, neck, lips, labial mucosa, buccal mucosa, 
gingiva, floor of the mouth, tongue, and palate with mouth mirrors to help visualise all 
surfaces.30 The tactile examination includes palpating the regional lymph nodes, tongue, 
and floor of the mouth.30 The Cochrane collaboration concluded by encouraging 
opportunistic screening and stating that GMPs and GDPs should continue to carry out 
visual and tactile examination of the oral cavity as an integral part of their routine daily 
work, and particular attention should be paid to high-risk individuals.27 
 
An expert European consortium formed in 2014 to systematically review the oral cancer 
and pre-cancer screening programmes in Europe. As there are no randomised controlled 
trials (RCTs), the findings were essentially the same as the Cochrane collaboration in 
2013.24, 25 In 2015 at the 11th Asian Congress of Oral & Maxillofacial Surgery (ACOMS), an 
expert consensus was reached to highlight the importance of oral cancer screening by 
various conventional and novel methods based on scientific research into their 
populations.26 In Asia the emphasis is on addressing the relatively high prevalence rate of 
oral cancer due to tobacco and betel nut consumption.26  
 
Monteiro et al. (2015) carried out separate invitational and opportunistic oral cancer 
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screening interventions in the city of Oporto in Portugal. The first part of this study was an 
invitational screening programme where residents of Oporto City were invited to attend on 
a designated screening day advertised via a mass media campaign.150 Pre-information 
regarding the oral cancer screening day were provided by screen shots on the Portuguese 
television, notices in newspapers and also by radio announcements.150 Additionally, the 
announcements of the screening day and central city location were by posters on local 
billboards and by distribution of leaflets at public places.150 The second part of the study 
was an opportunistic screening programme offered to consenting patients visiting for 
dental consultation (first appointment) in a public hospital of Oporto City.150 A total of 727 
individuals responded (277 males and 450 females) with a mean age of 54 years (range 
18-94), and an oral cancer screening tactile and visual examination was performed.150 A 
total of 267 (36.7%) were from the invitational oral cancer screening day. Twenty-two 
OPMLs, 9 cases of lichen planus, no erythroplakia, and no erythroleukoplakia were 
detected.150 In addition, two oral carcinomas were detected early, with both in the T1 stage 
of the disease and identified in the asymptomatic phase.150  
 
Initial outcomes recently published from an integrated outpatient-based screening 
programme for oral cancer in Taipei, Taiwan also support the need for screening in the 
asymptomatic phase. High-risk patients attending an outpatient facility at Far Eastern 
Memorial Hospital were identified using an automated system based on their response to 
questions regarding tobacco and betel nut usage, and then they were offered the 
opportunity to be screened with a standard visual and tactile oral cancer screening 
examination.32 A total of 8037 high-risk patients were recruited as participants to the 
screened cohort from the automated system; 1664 patients were identified with positive 
lesions, and 302 patients underwent a biopsy. Five patients were diagnosed with oral 
cancer and 121 with dysplastic OPMLs.32 The stage of disease at diagnosis of this 
asymptomatic cohort was compared to a symptomatic cohort presenting to the same 
outpatient facility for investigation of a symptomatic oral lesion.32 The symptomatic cohort 
comprised 157 patients with oral cancers and 61 with OPMLs, and, as expected, the 
automated screening programme identified earlier stages of oral cancers than the 
symptomatic cohort.32  
 
There is only one study investigating high-risk populations and oral mucosal disease in 
Australia. The Lesion Evaluation, Screening and Identification of Oral Neoplasia Study 
(LESIONS) aims to understand factors that may influence all oral mucosal disease in a 
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high-risk population with a particular focus on oral cancers and OPMLs.151 LESIONS has 
targeted two communities at high risk of oral cancer and OPMLs. The first was a low 
socio-economic region characterised by documented higher rates of tobacco and alcohol 
consumption.151 The second was an indigenous Australian population known to present 
with a higher rate of cancer-related modifiable risk factors, namely tobacco consumption 
and excessive alcohol use, which were 20% and 10% higher, respectively, than the 
general Australian population.151 The authors recently reported on the recruitment 
experiences and outcomes from the programme across ten screening sites within public 
and private dental clinics, indigenous health clinics and a community pharmacy. 151  A 
visual and tactile oral mucosal screening examination was completed on 1498 participants 
by one of 11 trained and calibrated dentists or oral health therapists.151  In these high-risk 
populations, oral mucosal lesions were detected in over half the cohort examined, but only 
16% were clinically non-homogenous and more likely to contain dysplasia or early 
malignant change.151  The results of biopsy and specialist review are not presented in the 
current report, however, the bivariate and multivariable analysis concludes that increased 
age, moderate/heavy tobacco consumption and high socioeconomic disadvantage are 
strongly associated with the prevalence of non-homogenous oral mucosal lesions.151   
 
Huang et al. (2015) have recently published their nation-wide analysis of 22024 cases of 
oral cancer in Taiwan after follow-up for 10 years.18 In their retrospective analysis they 
conclude that early diagnosis and early intervention before stage II can significantly 
improve life expectancy and decrease expected years of life lost to oral cancer.18 The 
results will be used to encourage the public to participate in oral cancer screening 
programmes.18 In Western populations where betel nut usage is minimal, population-
based annual or semi-annual screening for oral cancer is not cost-effective.23 Instead, 
targeting high-risk groups such as tobacco and alcohol consumers over 40 years of age to 
be opportunistically screened using a visual and tactile examination should be encouraged 
in the primary care setting.23  
 
2.5 Opportunistic Screening: Opportunities and Threats 
2.5.1 Patient Factors 
In Australia, for opportunistic screening to occur, asymptomatic patients need to attend a 
GMP or GDP and receive an oral cancer screening examination. Specific educational 
interventions to raise awareness of oral cancer and knowledge of the risk factors for 
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developing it is predicted to increase the number of patients requesting an oral cancer 
screening examination. In the UK, patients' knowledge of oral cancer is low compared to 
that of other types of cancer.152 A theory-based study found that a group at high risk for 
oral cancer wanted not only more information on the symptoms of oral cancer, but also 
more guidance on how to evaluate symptoms.153 Clear evidence of successful educational 
interventions includes the increased numbers of oral cancer screening examinations that 
have been performed over the years following the introduction of Oral Cancer Awareness 
Week (now Month) in the UK and Oral Cancer Awareness Month in the USA in 2000.154, 
155 
  
Many factors contribute to patient delay, such as perception of symptoms and illness and 
the behavioural responses they elicit, in addition to the major issue of accessibility to 
health care, including financial, structural, and personal barriers.144 These same factors 
present a threat to opportunistic screening strategies and opportunities for improvement. In 
Australia, each citizen has access to a free public health system with access to many 
GMPs under the government-funded Medicare scheme. However, citizens do not have 
access to a free dental health system. Australian citizens in the lowest income percentage, 
who are healthcare cardholders, are entitled to free dental treatment but are usually 
subject to long waiting lists unless emergent treatment is required. Research has shown 
that patients with oral lesions often consult their GMPs rather than their GDPs, even in the 
UK where there is greater access to free dental treatment.156, 157 A recent systematic 
review of patient acceptance of screening for oral cancer outside the dental setting 
showed that GMPs can be confident that acceptance of and satisfaction with oral cancer 
screening is high, particularly when patients have previously been educated about oral 
cancer.158 It is assumed, but not proven, that most patients with oral cancer in Australia 
would act similarly and present to GMPs in the symptomatic phase, given the lack of 
general subsidised access to GDPs under the Medicare scheme.  
 
This assumption will be tested in Chapter Three of this thesis, which investigates patients 
who have been diagnosed with oral cancer through the head and neck cancer clinic at the 
RBWH.  
 
2.5.2 General Medical and Dental Practitioners 
In order to achieve an early stage at diagnosis, a patient should ideally be diagnosed in 
the asymptomatic phase. This requires a GMP, GDP or other health professional to 
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perform an oral cancer screening examination. This takes approximately 90 seconds to 
perform after adequate training and includes extra-oral and intra-oral examinations in white 
light and manual palpation of related specific sites.159, 160 The examination should be 
accompanied by a review of the patient’s medical and dental history.159, 160 GMPs and 
GDPs should also be confident in the clinical signs of a malignant lesion and OPML, as 
this is key to reducing the anxiety associated with inappropriate referrals of benign 
pathologies.161 In December 2000 the UK Department of Health introduced Oral Cancer 
Awareness Week and also attempted to reduce professional delay by implementing the 
two-week rule system with regard to referrals of head and neck cancer. Under this system 
GMPs and GDPs would utilise a standard referral form and have the patients reviewed by 
a specialist within two weeks. Several audits of this intervention have shown it to be 
successful in reducing professional delay, but a high proportion of non-malignant lesions 
have been referred, with no significant improvement in stage of disease at diagnosis.162-165 
This highlights a low sensitivity among GMPs and GDPs and stresses the need for further 
education and training in assessing malignant lesions and OPMLs.162-165 Whilst newer 
techniques, such as toluidine blue staining, chemiluminescence, and autofluorescence, 
are becoming more established clinical tools for differentiating dysplastic from non-
dysplastic lesions and malignant from non-malignant tissue, the most suitable, accessible, 
and practical screening tool for a GMP or GDP remains a methodical extra-oral and intra-
oral examination in adequate white light.166, 167 
 
When oral cancer awareness among GMPs and GDPs is compared, there is significant 
divergence in most populations studied. A study in the UK found that GMPs were less 
likely to examine patients' oral mucosa routinely, were less likely to advise patients about 
risk factors for oral cancer, identified fewer risk factors for oral cancer, and felt less 
confident about diagnosing it from clinical appearance than their dental counterparts.168 In 
the USA a similar study concluded the GDPs were much more likely to feel adequately 
trained and regularly provide oral cancer screening examinations, but much less likely to 
discuss tobacco and alcohol cessation or to palpate the neck nodes.169 Similar studies in 
Saudi Arabia, Qazvin, Ireland, and Scotland reported similar key findings. In summary, 
GMPs are less intent on performing oral cancer screening, less skilful in performing oral 
cancer screening examinations, and less confident in diagnosing pathologies in the oral 
cavity than GDPs.170-173 A recent study of 640 GDPs in Australia showed that over 90% 
regularly perform oral mucosal screening examinations for all patients.31 Australian GDPs 
reported lack of training, confidence, time, and financial incentives as barriers to 
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performing mucosal screening to at least some degree.31 While most Australian GDPs 
manage referrals for oral mucosal pathology appropriately and promptly, only half believe 
in following up with the referred patients and only half believe they could influence a 
patient to quit smoking.31 
  
The intent of GMPs to conduct oral cancer screening has been investigated utilising the 
Theory of Planned Behaviour and this has identified barriers to conducting oral 
examinations for screening purposes in general medical practice. The results suggest 
considerable potential for improving intention to perform oral cancer screening in general 
practice.174 Suggested interventions include: 1) theory-based interventions, such as further 
training to enhance confidence, expertise, knowledge, and ease of examination, 2) 
provision of adequate equipment in the surgery (light and dental mirrors), and 3) 
introducing guidelines on opportunistic screening that increase motivation to comply, with 
more peers performing screening or an oral cancer awareness month.174 
 
In regard to GMP skill in oral cancer screening examinations, there is a statistically 
significant association between undergraduate and postgraduate teaching on examination 
of the oral cavity and whether practitioners felt confident in their ability to detect oral 
cancer.173 GMPs display decreased diagnostic confidence in detecting malignant or 
OPMLs. In fact, in a study of Irish GMPs, a statistically significant association was found 
between undergraduate and postgraduate teaching on the diagnosis of oral malignant 
disease and whether practitioners felt confident in their ability to detect oral cancer and 
OPMLs clinically.173 The authors concluded that the level of knowledge of GMPs needs to 
be addressed with appropriate initiatives both at undergraduate level and via continued 
medical education (CME).173 This raises the question of what is being taught at medical 
schools to improve these poor findings regarding the oral cancer awareness, intent to 
opportunistically screen, and skill in examination and diagnosis of GMPs when compared 
to GDPs. In addition, a potentially greater threat to improving opportunistic screening 
amongst GMPs was identified in a Scottish study in which a high proportion (66%) of 
GMPs felt strongly that oral cancer detection is the remit of the dental team.172 At present 
there is no data to suggest Australian GMPs are similar to their Scottish counterparts in 
knowledge, attitudes, and behaviour regarding oral cancer screening; however, if this 
attitude does pervade among Australian GMPs then it may prove difficult to change 
behaviour pertaining to opportunistic screening. At present the Royal Australian College of 
General Practitioners (RACGP) teaches that there is insufficient evidence to recommend 
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screening by visual inspection or by other screening methods.175 The RACGP identifies 
increased-risk individuals as smokers aged greater than 50 years, heavy drinkers, users of 
chewing tobacco or areca/betel nuts, and those exposed to excessive UV in the lip area.175 
If an individual is identified as having an increased risk, the RACGP encourages 
opportunistic examination of mouth and lips every 12 months but does not provide an 
examination description matching the desired nine-step visual and tactile oral cancer 
screening examination.30, 175 
 
2.5.3 Medical and Dental Student Education 
Studies comparing UK undergraduate medical and dental students showed that the 
students gave responses similar to those of their senior colleagues, suggesting there will 
be no improvement in the next generation of doctors regarding oral cancer screening.176 
Again, these results are echoed in studies from Iran, Nigeria, and the USA, and suggest a 
need to review the curriculum of medical and dental schools to improve awareness of and 
behaviour toward increased screening.177-181 
 
In fact, two significant studies investigated the curriculum for oral cancer teaching in the 
USA and UK. In 2011, the majority of the responding USA medical schools offered very 
little oral health education, with approximately 80% offering less than five hours of oral 
health curriculum over the entire course.182 Alarmingly, similar research 15 years earlier in 
the USA also concluded that oral cancer training lacked both adequacy and 
comprehensiveness.183 A logical conclusion is that there has been no improvement in 
training over this 15-year period. Similarly, in a 2011 UK study, undergraduate oral cancer 
teaching varied widely in terms of duration, format, and content, and the authors 
concluded that there is a need to develop a curriculum to address the important aspects of 
oral cancer from an evidence-based approach that can be integrated into the already-
crowded undergraduate medical curriculum.184 
 
2.5.4 Contribution of Bias 
Whilst diagnosis in the asymptomatic phase from opportunistic oral cancer screening is 
worth achieving, it should be noted that the success of any screening intervention could be 
affected by length-time and lead-time bias.  
 
Length-time bias occurs when the possibility of detecting aggressive (rapid-growing) oral 
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cancers by screening is low due to the fact that the period until symptoms arise is short. In 
contrast, less aggressive (slow-growing) cancers have longer periods until symptoms arise 
and are easier to detect by screening.146 This phenomenon may lead a researcher to think 
that an early diagnosis improves prognosis, when in fact the screening approach simply 
detects tumours that are biologically less aggressive.23 
 
Lead-time bias occurs when survival following an oral cancer diagnosis seems better when 
cases are diagnosed early, when in fact the patient did not live any longer than he or she 
would have if the cancer had been diagnosed in the symptomatic period.23 
 
The contribution of both of these potential sources for bias must be considered when 
analysing data on the success of screening programmes. To date there is insufficient 
evidence to conclude that screening alters disease-specific mortality in an asymptomatic 
person seeking GMP or GDP care.2 Of course, insufficient evidence only means that there 
no methodologically sound studies are available to support the given screening 
approach.146 
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CHAPTER THREE: AUSTRALIAN PATIENTS WITH ORAL CANCER 
 
3.1 Introduction 
Oral cancer has one of the highest mortality rates among all malignancies worldwide.3 
Over the last twenty years the incidence of oral cancer has increased throughout 
developed regions globally, including Australia, New Zealand, North America, Europe, and 
parts of East Asia.185, 186 Overall, the five-year survival rate is approximately 50% for all 
anatomical sites and stages.11 The most important prognostic marker for oral cancer 
remains tumour stage at diagnosis.6, 12 Unfortunately, most oral cancers lack early 
symptoms, and hence by the time symptoms do develop and stimulate a patient to seek a 
diagnosis, the disease has already reached advanced stage, resulting in more than 60% of 
patients being diagnosed with stage III and IV disease.13, 14The reported five-year survival 
rate for stage III or IV oral cancer ranges between 15% and 55%.15-18 Survival rates are 
significantly improved if the disease is treated at an early stage, ideally when the patient is 
asymptomatic with a tumour less than 2cm in diameter and with less than 4mm of 
invasion.20 Therefore, early detection of malignant lesions and oral potentially malignant 
lesions (OPMLs) is an important goal for reducing morbidity and mortality.14, 15, 21, 22 
 
Huang et al. (2015) recently published an analysis of 22,024 pathologically verified cases 
of oral cancer in Taiwan after follow-up for 10 years.18 In their retrospective analysis, they 
concluded that early diagnosis and intervention before stage II can significantly improve 
life expectancy and decrease expected years of life lost to oral cancer.18 These results will 
be used to encourage the public to participate in oral cancer screening programmes.18 The 
Cochrane collaboration and an expert European consortium agreed that whilst population-
based annual or semi-annual screening for oral cancer is not cost-effective, targeting high-
risk groups—such as tobacco and alcohol consumers over 40 years of age—with 
opportunistic screening using a visual and tactile examination should be encouraged in the 
primary care setting.23-25 Opportunistic oral cancer screening should remain an integral part 
of routine daily work for GMPs and GDPs, with particular attention paid to high-risk 
individuals.27 
 
In Australia the most significant risk factors for the development of oral cancer are 
increased age, tobacco, and alcohol consumption.28, 29 While it is rare to diagnose oral 
cancer (excluding lip) under the age of 40 years in Australia, an increasing number of 
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cases show no prior alcohol or tobacco use; often these are women under 45 years of 
age.2, 15, 54, 106 Ongoing research has suggested a role for HPV in such cases, although this 
has not been confirmed.2, 15, 54, 106 The incidence of male and female HPV-related 
oropharyngeal cancers in Australia has significantly increased annually across both 
genders in line with global trends.91 
 
To date only one Australia cohort of patients has been investigated regarding patient 
awareness, risk factors and components of diagnostic delay, however this study was 
limited to patients attending a private specialist oral medicine clinic, and most of the 
pathology noted was OPMLs, with only 8 cases of OSCC.187 No Australian cohort of 
patients with newly diagnosed and pathologically confirmed oral cancer has been 
investigated regarding patient awareness, knowledge of risk factors, actual risk factors, 
patient delay, professional delay, diagnostic delay and access to health practitioners in the 
Australian health system in the asymptomatic phase prior to diagnosis. Much research has 
focused on review of patient and professional delay, but this research precedes the patient 
delay phase and focuses on the asymptomatic phase where the oral cancer may be 
present and detected at an earlier stage of disease.32 A key aim is to identify missed 
opportunities for early diagnosis of malignant lesions or OPMLs by investigating patient 
interactions with GMPs and GDPs in the asymptomatic phase. 
 
3.2 Hypotheses 
1. Oral cancer patients at the RBWH had poor awareness of oral cancer prior to their 
diagnosis. 
2. Oral cancer patients at the RBWH had poor knowledge of risk factors prior to their 
diagnosis. 
3. Oral cancer patients at the RBWH had one or more known risk factors for oral 
cancer at the time of diagnosis. 
4. Oral cancer patients at the RBWH had exposure to health practitioners in the 
asymptomatic phase in the preceding months or years before awareness of 
symptoms or diagnosis occurred. 
5. No oral cancer patient at the RWBH had ever been opportunistically screened for 
oral cancer by a GMP in the asymptomatic phase. 
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3.3 Aims 
1. To assess participants' awareness of oral cancer prior to diagnosis. 
2. To assess participants' knowledge of risk factors prior to diagnosis. 
3. To identify participants' risk factors for oral cancer at diagnosis. 
4. To assess patient, professional, and total diagnostic delay. 
5. To identify whether participants had opportunities in the Australian health system to 
receive an opportunistic oral cancer screen in the asymptomatic phase.  
 
3.4 Methods and Materials  
Ethical Approvals 
The study protocol was approved by the University of Queensland Dental Science 
Research Ethics Committee (1217) and the RBWH Human Research Ethics Committee 
(HREC/14/QRBW/82). 
 
Study Design 
Following extensive review of the literature, a questionnaire was designed to address the 
study aims. A cohort of Australian patients diagnosed with pathologically verified oral 
cancer (excluding lip) through the RBWH Head and Neck Clinic under the Metro North 
Hospital and Health Service of Queensland Health were invited to participate in the year-
long study. The validity and reliability of the questionnaire was established with a small 
pilot group of six patients, utilising the test and re-test method.  
 
Participant Recruitment 
The research study pack contained an introductory cover letter on Queensland Health 
letterhead signed by the site coordinator, a participant information form, a form for 
informed consent, the questionnaire, and a professionally addressed and stamped return 
envelope for return of the questionnaire. As recruitment in a retrospective manner, the 
research study pack was mailed, utilising the modified Dillman method known to increase 
response rates, to patients who were recently diagnosed with an oral cancer (excluding lip) 
three months prior to the ethical clearance date (April 2014).31, 187-189 In a prospective 
manner, new patients attending the RBWH Head and Neck Clinic until January 2015 who 
were diagnosed with an oral cancer (excluding lip) were invited to participate on the day of 
their attendance by the approved site coordinator or their delegate employee of 
Queensland Health; this was independent from the researchers. The participants were 
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able to freely consent and either complete the questionnaire at the clinic or return it via 
pre-paid mail. The questionnaire responses were initially identifiable to allow a follow-up 
phone call for clarification of responses if required, and to award the incentive (“a new 
iPad”), which was randomly drawn by the chief investigator at the conclusion of data 
collection. 
 
Questionnaire 
The questionnaire consisted of 36 open, multiple-choice, or closed questions investigating 
demographics; awareness of oral cancer before diagnosis; knowledge of risk factors 
before diagnosis; asymptomatic or symptomatic diagnosis; symptoms developed; referral 
pathway; dates for calculation of patient, professional, and diagnostic delay; analysis of 
interactions with GMPs, GDPs, and any other health professionals in the asymptomatic 
phase before diagnosis; and any risk factors the participant had prior to diagnosis. A full 
copy of the questionnaire is given in Appendix A. 
 
Data Analysis 
Completed questionnaires were de-identified, manually coded and recorded into Microsoft 
Excel (Microsoft Corporation, Washington, USA) to allow statistical analysis of binary and 
non-binary responses. Insufficient numbers of patients were recruited in the year to allow 
subset analysis of patient groups with any significance. The results were expressed as 
proportions and frequency count charts calculated using Microsoft Excel (Microsoft 
Corporation, Washington, USA)  
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3.5 Research Results 
Unless otherwise stated, all percentages reported are the percentage in agreement. 
 
3.5.1 Response Rate and Demographics 
22 of 27 questionnaires mailed to the retrospective group and 81 of 85 questionnaires 
mailed to the prospective group were returned, giving a total of 103 questionnaires 
returned and an overall response rate of 92%. The median age of participants was 65 
years, and 74 (72%) were male and 29 (28%) were female; these were the only 
demographics collected via Questions 1 and 2.  
 
3.5.2 Patient Awareness of Oral Cancer 
Table 3.1 presents the responses to Questions 3 to 10 regarding patients' awareness of 
oral cancer before receiving a diagnosis. Of interest is that 6% of participants had a 
previous diagnosis of oral cancer and 25% had a friend or relative with a previous 
diagnosis of oral cancer, and yet in spite of that exposure, only 17% stated that they had 
ever read anything about oral cancer prior to their own diagnosis. If a participant had 
answered 'no' to Questions 3 through 9, then they were left with a positive response to 
Question 10, highlighting, after clarification of responses by the chief investigator, that 46% 
had never heard of oral cancer until their diagnosis. 
 
Table 3.1: Patient Awareness of Oral Cancer 
 
 
 Yes No 
 n=103 n % n % 
Have you worked with patients with oral cancer in a health care 
role? 
3 3% 100 97% 
Have you had a previous diagnosis of oral cancer? 6 6% 97 94% 
Have you had a previous diagnosis of oral cancer in your 
extended family? 
12 12% 91 88% 
Have you had a previous diagnosis or oral cancer in a friend? 13 13% 90 87% 
Have you heard of a previous diagnosis of oral cancer in 
someone not known to you but you had heard about it from others 
or from talking or online? 
31 30% 72 70% 
Have you ever read anything about oral cancer prior to your 
diagnosis? 
17 17% 86 83% 
Had you never heard of oral cancer until you were diagnosed? 47 46% 56 54% 
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3.5.3 Patient Knowledge and Risk Factors 
 
Table 3.2: Patient Knowledge of Risk Factors vs. Actual Risk Factors 
 Patient knowledge Risk factor present 
n=103 n % n % 
Tobacco 54 52% 69 67% 
Alcohol 15 15% 68 66% 
Betel Nut 0 0% 2 2% 
HPV 2 2% 5 5% 
Poor Diet 0 0% 11 11% 
Age > 40 years 0 0% 98 95% 
Male 0 0% 74 72% 
Family History 3 3% 3 3% 
OPML 3 3% 3 3% 
Poor Dental Hygiene 1 1% Not assessed NA 
 
Table 3.2 presents the responses to Questions 11 and 34, highlighting the fact that 
approximately half (52%) of participants identified tobacco consumption (smoking or 
smokeless) as a risk factor, despite 67% using tobacco themselves. In addition, only 15% 
were aware that alcohol consumption is a risk factor, in contrast to 66% being regular 
consumers of alcohol. Three participants (3%) identified an OPML as a risk factor, due to 
all three being repeatedly monitored for their own OPML via clinical review. Overall, 
participants are low in knowledge of other risk factors, such as human papilloma virus 
(HPV), betel (areca) nut consumption, age, sex (male), and a diet poor in fresh fruit and 
vegetables. 95% were over 40 years of age at diagnosis, and 67% and 66% were regular 
consumers of tobacco and alcohol, respectively. 
 
3.5.4 Patient Diagnostic Process 
Table 3.3 represents the responses to Questions 12-15 and 17, and reveals that only 7% 
of all participants were diagnosed in the asymptomatic phase, and all these were by health 
practitioners with a dental qualification. The remaining 93% of participants were only 
diagnosed once symptoms had developed, with the large majority (73%) electing to see a 
GMP rather than a GDP (14%) for explanation of their symptoms. The three most common 
symptoms that led participants to present to a health practitioner were pain (60%), a 
lump/lesion (52%), and an ulcer/sore (43%).  
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Table 3.3: Patient Diagnostic Process 
 
95 of 96 participants were able to recall the date of symptoms and date of attending their 
initial health practitioner. Questions 16, 18, and 19 allow calculation of the patient and 
professional delay (Figure 3.1) and the overall diagnostic delay (Figure 3.2). The median 
patient delay was 14 days. The median professional delay was 34 days. The median of 
total diagnostic delay was 62.5 days, or 9 weeks. 
 n % 
Asymptomatic Diagnosis (Yes responses= 7, n=103) 7 7% 
Diagnosed by Dental Practitioner 4 4% 
Diagnosed by Dental Specialist (Oral Medicine/Oral    
Pathologist) 
2 2% 
Diagnosed by General Medical Practitioner 0 0% 
Diagnosed by OMF Surgeon (monitoring OPML) 1 1% 
Symptomatic Diagnosis (Yes responses = 96, n=96) 96 93% 
Diagnosed by Dental Practitioner 14 14% 
Diagnosed by Dental Specialist (Oral Medicine/Oral Pathologist) 0 0% 
Diagnosed by General Medical Practitioner 75 73% 
Diagnosed by Medical Specialist 4 4% 
Diagnosed by Emergency Physician 3 3% 
What symptoms did you develop before diagnosis? (n=96)     
Altered Neurology 5 5% 
Altered Speech 2 2% 
Bleeding 4 4% 
Erythema 2 2% 
Lump/Lesion 50 52% 
Pain 58 60% 
Ulcer/Sore 41 43% 
Weight Loss 4 4% 
 
 
30 
 
Figure 3.1: Patient and Professional Delay 
 
 
 
Figure 3.2: Diagnostic Delay 
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3.5.5 Encounters with Medical Profession in Asymptomatic Phase 
Table 3.4 displays the responses to Questions 20-26 and highlights the fact that 92% of 
participants had seen their GMP in the preceding two years before diagnosis, 80% had 
seen their GMP within the last six months (37% less than one month, 28% between one 
and three months, and 15% between three and six months) and 63% saw their GMP at 
least three times a year. These responses show there are many attendances where 
opportunistic oral cancer screening could have been performed. Of concern is that while 
84% of participants state they have a regular GMP, only 3% of their GMPs had ever 
discussed the risk factors for oral cancer, and only 6% responded that their GMPs had 
ever performed an oral cancer screening examination on them.  
 
Table 3.4: Patient Encounters with General Medical Practitioners 
 Yes No 
n=103 n % n % 
Did you access a GMP in Australia in the preceding two years for 
any other reason? 
94 91% 9 9% 
Do you have a regular GMP in Australia that you would call “your 
GP”?  
86 83% 17 17% 
At any time, has a GMP in Australia discussed oral cancer or its 
risk factors with you?  
3 3% 100 97% 
At any time, has a GMP in Australia performed oral cancer 
screening examination on you?  
6 6% 97 94% 
	  	   	  	   	  	   	  	   	  	  
Prior to symptoms or diagnosis (for those participants with an asymptomatic diagnosis), when was the last visit 
to a GMP? (N=103) 
	  	  
< 1 month before symptoms 38 37% 	  	   	  	  
1 - 3 months before symptoms 29 28% 	  	   	  	  
3 - 6 months before symptoms 15 15% 	  	   	  	  
6 - 12 months before symptoms 8 8% 	  	   	  	  
> 12 months before symptoms 6 6% 	  	   	  	  
Unknown 7 7% 	  	   	  	  
Participant has a regular GMP and lists average number of visits per year to their 
regular GMP (n=86) 
  	  	   	  	  
0 3 3% 	  	   	  	  
1 9 9% 	  	   	  	  
2 9 9% 	  	   	  	  
3 10 10% 	  	   	  	  
4 18 17% 	  	   	  	  
5+ 37 36% 	  	   	  	  
Participant has no regular GMP and lists average number of visits 
per year to any GMP (n=16) 
    	  	   	  	  
0 10 10% 	  	   	  	  
1 2 2% 	  	   	  	  
2 1 1% 	  	   	  	  
3 1 1% 	  	   	  	  
4 2 2% 	  	   	  	  
5+ 0 0% 	  	   	  	  
Unknown 1 1% 	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3.5.6 Encounters with Dental Profession in Asymptomatic Phase 
 
Table 3.5 presents the responses to Questions 27-33 and reveals that fewer participants 
(65%) had seen a GDP in the preceding two years before they developed symptoms, and 
only 47% had a regular GDP. Of those who had a regular GDP, most attended their dentist 
only once or twice per year. The remaining 53% did not have a regular GDP and 
predominantly would only see a dentist for an emergent dental problem, with the vast 
majority stating zero times per year as their average rate of dental visits. These questions 
also revealed that 6% of participants had their risk factors for oral cancer discussed with 
them by a GDP and a GDP had performed an oral cancer screening examination on 9%. 
Table 3.5: Patient Encounters with General Dental Practitioners 
 Yes No 
n=103 n % n % 
Did you access a GDP in Australia in the preceding two years for any 
other reason? 
67 65.0% 36 35.0% 
Do you have a regular GDP in Australia that you would call “your 
dentist”?  
48 46.6% 55 53.4% 
At any time, has a GDP in Australia discussed oral cancer or its risk 
factors with you?  
6 5.8% 97 94.2% 
At any time, has a GDP in Australia performed oral cancer screening 
examination on you?  
9 8.7% 94 91.3% 
          
Prior to symptoms or diagnosis (for those participants with an 
asymptomatic diagnosis), when was the last visit to a GDP? 
n %     
< 1 month before symptoms 12 11.7%     
1 - 3 months before symptoms 10 9.7%     
3 - 6 months before symptoms 14 13.6%     
6 - 12 months before symptoms 18 17.5%     
> 12 months before symptoms 24 23.3%     
Unknown 25 24.3%     
Participant has a regular GDP and lists average number of visits per year 
to their regular GDP (n=48) 
        
0 2 1.9%     
1 22 21.4%     
2 17 16.5%     
3 4 3.9%     
4 2 1.9%     
5+ 1 1.0%     
Participant has no regular GDP and lists average number of visits per 
year to any GDP (n=55) 
        
0 48 46.6%     
1 5 4.9%     
2 0 0.0%     
3 0 0.0%     
4 1 1.0%     
5+ 1 1.0%     
Unknown 0 0.0%     
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3.6 Discussion 
Prevention and early stage of diagnosis are promising for oral cancers because of known 
risk factors and the relative ease of identifying oral cancers and OPMLs by a simple oral 
cancer screening examination. For an oral cancer screening examination to be performed 
in the primary healthcare setting requires either the patient to be sufficiently aware of oral 
cancer and risk factors to request one, or the GMP or GDP to be aware of oral cancer and 
the patient’s risk factors and initiate an oral cancer screening examination. The first study 
aim was to assess participants' awareness of oral cancer. Unfortunately, this study—of 
patients with newly-diagnosed oral cancer presenting to a public hospital head and neck 
clinic—reports one of the lowest scores in the literature regarding awareness of oral 
cancer, with 46% stating they had never heard of oral cancer until their diagnosis. This is 
in contrast to reports from the USA in which only 14-15.5% of adults had never heard of 
oral cancer.190, 191 The low awareness of oral cancer in this Australian cohort is highlighted 
by the response from 67% of current participants that they had been regular consumers of 
tobacco in Australia where plain packaging of tobacco products is legislated. This 
packaging contained graphic images of lip, mouth, tongue, and lung cancer for many years 
preceding this study. This suggests that even plain packaging of tobacco products has 
failed to raise awareness of oral cancer in a high-risk population. Another Australian study 
investigated 101 patients referred with a suspicious oral lesion to a private oral medicine 
clinic.187 These patients reported being far more aware of oral cancer, with 91.8% having 
heard about someone with oral cancer.187 Patients in this study expected that both GDPs 
and GMPs should check for and be able to explain oral mucosal pathology, raising the 
question of whether the general public might expect similar standards of care.187 The 
demographics of these two Australian cohorts are very different, making comparison 
between the two groups difficult; however, there is an obvious wide divide in awareness of 
oral cancer when private and public patients are compared. 
 
The second and third study aims were to identify participants' knowledge of risk factors 
and their actual risk factors (Table 3.2). With regard to actual risk factors for oral cancer, 
this Australian cohort is consistent with results reported from other cohorts from developed 
nations, in that the most significant risk factors identified are increased age, tobacco use, 
and alcohol consumption.28, 29 95% were over 40 years of age at diagnosis, and 67% and 
66% were regular consumers of tobacco and alcohol, respectively. There was poor 
knowledge of these important risk factors and almost no knowledge of HPV as a risk 
factor. A recent international large pooled study estimated the population attributable risks 
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for tobacco and alcohol use to be 64% (95%CI:45-75%), showing these two risk factors 
alone are responsible for a large number of cases.28 The poor knowledge of risk factors for 
oral cancer logically follows from the cohort’s generally poor awareness of oral cancer. 
Over the last 20 years the anti-tobacco campaign in Australia has been very strong, so it is 
not surprising that approximately half (52%) of participants identified tobacco consumption 
(smoking or smokeless) as a risk factor for oral cancer. However, considering the volume 
of anti-tobacco campaign material in the Australian community, and that 67% of 
participants reported using tobacco themselves, a much higher figure of 90-100% was 
expected. Additionally, only 15% were aware that alcohol consumption is a risk factor, 
while 66% were regular consumers of alcohol. In contrast to the strength of the anti-
tobacco campaign, there is very little promotion of the health risks of alcohol in Australia.  
 
The lack of awareness and knowledge in our Australian cohort can be improved with 
specific educational interventions, either in the general population or targeted to high-risk 
groups. The Lesion Evaluation, Screening and Identification of Oral Neoplasia Study 
(LESIONS) aims to understand factors that may influence all oral mucosal disease in a 
high-risk population with a particular focus on oral cancers and OPMLs.151 LESIONS 
targeted two Australian communities at high risk of oral cancer and OPMLs, mostly in the 
dental setting but also at a community pharmacy location. The first was a low socio-
economic region characterised by documented higher rates of tobacco and alcohol 
consumption.151 The second was an indigenous Australian population known to present 
with a higher rate of cancer-related modifiable risk factors, namely tobacco consumption 
and excessive alcohol use, which are 20% and 10% higher, respectively, than the general 
Australian population.151 Whilst the exact numbers were not captured, the authors noted a 
high rate of patient refusal when approached opportunistically before or after scheduled 
dental appointments.151 Common patient barriers identified were perceived time pressure, 
embarrassment regarding the condition of the dentition (when screening attempted at 
community pharmacy), unwillingness to know if disease was detected, lack of concern and 
lack of pain.151 
  
Many interventions have been tested and reported in the literature, and some have been 
shown to increase the number of patients requesting an oral cancer screening 
examination. Recently published results of an invitational and opportunistic oral cancer 
screening intervention in Oporto, Portugal reported on a total of 727 participants with a 
mean age of 54 years. After a visual and tactile oral cancer screening examination was 
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performed, many OPMLs were diagnosed, but of most significance is that two oral cancers 
were detected, both asymptomatic and in the T1 stage.150 Awareness and knowledge of 
oral cancer is key for patients to accept an invitation of oral cancer screening. This is most 
notable in the recently published data from a novel approach to oral cancer screening at 
Far Eastern Memorial Hospital in Taiwan. High-risk patients attending an outpatient facility 
were identified using an automated system based on their responses to questions 
regarding tobacco and betel nut usage, and they were then offered the opportunity to be 
screened with a standard visual and tactile oral cancer screening examination.32 A total of 
38 693 patients were identified as high-risk, yet only 8037 (20.8%) were recruited as 
participants in the screened cohort from the automated system.32 This means that 
approximately 80% were advised that they were at high risk for developing oral cancer yet 
declined a free oral cancer screening examination. The reasons these Taiwanese patients 
declined the invitation are most likely multifactorial, as with all health behaviours and 
outcomes, but a significant component is likely to be poor awareness and knowledge of 
oral cancer. This was evident in UK pilot research exploring ways to improve 
understanding of individuals at risk of oral cancer and their attitudes toward early detection 
interventions. In particular, the target population for opportunistic screening activities was 
shown to require further persuasion that their lifestyle choices (tobacco and alcohol) 
contributed to an increased risk of oral cancer.153 Over the last decade following the 
introduction of an oral cancer awareness week (now month) in the UK and the Oral Cancer 
Awareness Month in the USA in 2000, increasing numbers of oral cancer screening 
examinations have been performed each year.154, 155 It is still difficult to elucidate whether 
the high-risk target population are being reached, though, or whether the general 
population is gaining increased awareness and knowledge and becoming more accepting 
of screening activity. 
 
Our fourth study aim was to assess patient, professional, and total diagnostic delay. In 
addition to the challenge of finding and diagnosing these lesions in the early stages of 
disease, some literature also reports that a significant determinant of oral cancer survival 
is diagnostic delay. Diagnostic delay generally refers to the time between the patient's first 
awareness of symptoms and a definitive diagnosis following specialist review, during 
which a tumour can become locally invasive or disseminate via lymphovascular or 
perineural spread.25, 128, 129 In turn, diagnostic delay is commonly divided into patient delay, 
which refers to the time between the beginning of symptoms and when the patient first 
meets with a professional for a consultation regarding diagnosis,130 and professional delay, 
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or the time that has elapsed from this initial consultation, often in the primary care setting, 
until a definitive diagnosis is made, often after referral to a specialist setting. Total 
diagnostic delay averages from three to six months and is fairly evenly distributed between 
patient and professional delay.23 
 
A study by Esmaelbeigi et al. (2014) of delay in oral cancer showed that 71.4% of Iranian 
study participants were diagnosed at the advanced stage (III-IV),132 and the medians of the 
patient, professional, and total delays in this Iranian cohort were 45, 86, and 140 days, 
respectively.132 A 2009 systematic review reported that total diagnostic delay was 
associated with a more advanced tumour stage at diagnosis, with a pooled relative risk 
(RR) of 1.47 (95% CI: 1.09–1.99) for oral cancers and a diagnostic delay greater than one 
month resulting in a pooled RR of 1.69 (95% CI: 1.26-2.77).33 In the same year a 
conflicting systematic review including all head and neck cancers, not purely oral cancers, 
reported no association between diagnostic delay in head and neck cancers and tumour 
stage at diagnosis.143 Seoane et al. (2010) further challenged the strength of the 
relationship via a statistical analysis of 83 OSCC cases, which showed that when the 
analysis was adjusted for tumour stage at diagnosis (I-II vs. III-IV), proliferative activity 
resulted to be an independent prognostic factor for survival, whereas diagnostic delay did 
not influence survival significantly.144 Research on professional delay and mortality in 
tongue cancer is even more paradoxical, as shorter professional delay trends toward 
worse survival rates, an unreasonable statistical outcome.140, 145 This paradoxical 
response whereby diagnostic delay, tumour staging, and prognosis are inversely related 
has also been described in breast, cervical, lung, colon, renal, and urethral cancer, and the 
data suggest that stage at diagnosis and survival are affected more by tumour biology 
(rapid growth, poorly differentiated etc.) than by diagnostic delay.146 Despite this 
controversy, diagnostic delay and its components remain useful for characterising a typical 
patient's journey through the health system toward treatment. Before this thesis there were 
no Australian data from a head and neck clinic that enabled calculation of patient, 
professional, and diagnostic delay in oral cancer. We have provided this data (Figures 3.1 
and 3.2) and found a median total diagnostic delay of 62.5 days, or 9 weeks, which is 
better than most reports from other countries in the literature. This indicates that there may 
be opportunities to improve the efficiency of the referral and investigation pathway, 
especially when the patient delay component has a median value of two weeks. 
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Causes of patient delay relate to psychosocial issues, such as perception of symptoms 
and illness, and the behavioural responses they elicit, in addition to the major issue of 
accessibility to health care, including financial, structural, and personal barriers, such as 
beliefs, culture, and language.131 In the Iranian cohort, patients with primary-level 
education had a 70% lower risk of delay compared to illiterate patients, and the risk was 
lower again among patients who had diploma-level or college-level education.132 A recent 
study investigating barriers to oral cancer screening in rural African-Americans showed 
three primary patient barriers to screening: lack of knowledge of oral cancer and its 
symptoms accounted for 31.8% of all barriers mentioned, lack of financial resources or 
health insurance for 25.0%, and fear of screening and diagnosis for 22.9%.133 Howell et al. 
(2013) placed these barriers within the Theory of Planned Behaviour and concluded that 
interventions aimed at increasing oral cancer screening should first focus on changing 
people's attitudes about screening by increasing knowledge about oral cancer and 
reducing fear.133 
 
Identifying causes of professional delay provides an opportunity to develop interventions 
which may lead to increased opportunistic screening of the higher-risk target population. 
Research has shown that lack of knowledge regarding the main locations of oral cancer, 
low suspicion of oral cancer, and low levels of skill and confidence to perform a full head 
and neck examination with appropriate equipment are prevalent in the general medical 
community.131, 134-136 The presence of patient co-morbidities has also been shown to result 
in clinicians focusing their attention on the existing disorders.137-139 Prescription of 
medicines (such as analgesics) in the primary care setting (OR = 5.3, 95% CI 2.2–12.9), 
history of dental procedure, (OR = 6.8, 95% CI 1.7–26.9), and history of loose teeth 
increased the risk of delay four times (OR = 4.0, 95% CI 1.6–9.8) and were associated 
with a higher risk of delay compared to patients who were biopsied from the beginning.132 
 
Rather than focusing on delay as a major contributor to tumour stage at diagnosis and 
survival, the focus should be shifted to identifying lesions in the asymptomatic period. 
There is no disputing the overwhelming volume of literature showing that many patients 
are diagnosed in the symptomatic phase, often at an advanced stage (III-IV) of disease. 
As research on patient delay by definition deals with the symptomatic phase, if an early 
stage diagnosis is to be achieved, then future research efforts need to focus on improving 
oral cancer screening in the asymptomatic phase through appropriate novel screening 
strategies.  
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Our final study aim was to identify whether participants had opportunities in the Australian 
health system to receive an opportunistic oral cancer screen examination in the 
asymptomatic phase. According to the WHO and NIDCR, an oral cancer screening 
examination should include a visual examination of the face, neck, lips, labial mucosa, 
buccal mucosa, gingiva, floor of the mouth, tongue, and palate, with mouth mirrors to help 
visualise all surfaces.30 The tactile examination includes palpating the regional lymph 
nodes, tongue, and floor of the mouth.30 In this patient questionnaire an abridged version 
of the above definition was provided in the section asking participants to answer questions 
about their encounters with GMPs and GDPs in the asymptomatic phase. The responses 
(Tables 3.4 and 3.5) reveal that opportunistic oral cancer screening could have been 
performed at many attendances.  
 
In Australia, every citizen has access to a free public health system with access to many 
GMPs under the Medicare scheme. In contrast, access to the dental health system is not 
free; only Australian citizens in the lowest income percentage are eligible and entitled to 
free public dental treatment, and access is usually subject to long waiting periods unless 
emergent treatment is required. Research has shown that patients with oral lesions often 
consult their GMP rather than their GDP, even in the UK where there is greater access to 
free dental treatment.156, 157 The preference for presentation to GMPs has held true in this 
study, with 80% having seen a GMP within the last six months and 63% seeing their own 
regular GMP at least three times a year. In contrast, only 35% had seen a GDP within the 
last six months and only 6.8% visited their own regular GDP at least three times a year. 
While less than half (47%) of patients have their own regular GDP, 84% have their own 
regular GMP. Despite the latter high figure, only 3% of these patients, who were mainly 
high-risk, reported that their regular GMPs had ever discussed their risk factors for oral 
cancer, and only 6% had ever received an oral cancer screening from them. These results 
present an opportunity to target new education interventions to GMPs toward increasing 
opportunistic oral cancer screening in the primary medical care setting.  
 
A previous study of Australian GDPs reported that 94.5% checked all new patients for oral 
mucosal pathology and 85.7% checked all recall/review patients for oral mucosal 
pathology.31 In conflict with this, participants in our study responded that only 9% had a 
GDP ever perform an oral cancer screening examination on them and only 6% had a GDP 
ever discuss their risk factors for oral cancer with them. Perhaps the definition provided for 
an oral cancer screening examination would make these participants think that no GDP 
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had palpated their neck or face and therefore they had never been formally screened. 
Perhaps the study of Australian GDPs should have asked if GDPs are performing visual 
and tactile oral cancer screening examinations as per the definition given by the WHO and 
NIDCR. It is questionable whether 94.5% of GDPs are performing all nine steps of the 
visual and tactile oral cancer screening examination on every new patient, as the evidence 
suggests that GDPs are much less likely to palpate the neck nodes.169 All future 
questionnaires relating to oral cancer screening should define the standard visual and 
tactile examination steps described in that definition as a way of standardising the 
research in this field.  
 
Only 47% of participants have a regular GDP, and most only attend once or twice per 
year. The remaining 53% do not have a regular GDP, and predominantly only see a 
dentist for an emergent dental problem, the average rate of dental visits being zero times 
per year for the vast majority. The evidence suggests that GDPs are more skilled and 
confident in performing the oral cancer screening examination than their medical 
counterparts.168, 170-173 However, the low attendance rate for GDPs in Australia suggests 
that targeting education interventions toward increasing oral cancer screening with GDPs 
would be less productive than that with GMPs, where the target population is more likely to 
attend. A recent systematic review of patient acceptance of screening for oral cancer 
outside the dental setting showed that GMPs should be confident that acceptance of and 
satisfaction with oral cancer screening is high, particularly when patients have previously 
been educated about oral cancer in the waiting room.158 In short, the results clearly show 
that participants had many opportunities in the Australian health system to receive an 
opportunistic oral cancer screening examination before their diagnosis.  
 
Table 3.6 presents a tabulated summary of outcomes to the five hypotheses tested in this 
study. It is clear that in Australia, there is a deficiency in both patients and GMPs regarding 
oral cancer. It is also clear that the target population for oral cancer screening is attending 
the primary medical healthcare setting in Australia. Asymptomatic diagnosis of early-stage 
disease is definitely possible in the primary medical healthcare setting in Australia, and 
future interventions should be targeted to increasing awareness and knowledge of oral 
cancer for both patients and GMPs. 
 
 
 
 
 
40 
Table 3.6: Hypotheses Results (Oral Cancer Patients) 
Hypotheses Tested Outcome 
Oral cancer patients at the RBWH had poor 
awareness of oral cancer prior to their diagnosis. 
Null hypothesis true 
46% never heard of oral cancer 
Oral cancer patients at the RBWH had poor 
knowledge of risk factors prior to their diagnosis. 
Null hypothesis true 
52% identify tobacco as risk factor 
15% identify alcohol as risk factor 
Oral cancer patients at the RBWH had one or more 
known risk factors for oral cancer at the time of 
diagnosis. 
Null hypothesis true  
All patients had at least one risk factor 
Oral cancer patients at the RBWH had exposure to 
health practitioners in the asymptomatic phase in the 
preceding months or years before awareness of 
symptoms or diagnosis occurred. 
Null hypothesis true 
All patients had accessed a health 
practitioner in the asymptomatic phase 
No oral cancer patient at the RWBH had ever been 
opportunistically screened for oral cancer by a GMP in 
the asymptomatic phase. 
Alternative hypothesis true 
6% reported screening by GMP 
(9% reported screening by GDP) 
 
3.7 Conclusion 
Australian oral cancer patients at the RBWH reported very poor awareness of oral cancer 
and poor knowledge of risk factors prior to their diagnosis. Improving patient awareness of 
oral cancer and knowledge of their own risk factors is important if patients are to request 
an oral cancer screening examination or respond to an invitation to receive one in the 
primary healthcare setting. Health promotion messages should convey information that 
helps patients know when to consult their health care professional.192 For example, to 
increase screening of asymptomatic individuals, media messages should focus on 
encouraging patients over 40 who use tobacco products or drink alcohol regularly to see a 
local GMP or GDP for a quick and painless oral cancer screening examination. To 
increase screening of symptomatic individuals, media messages should focus on advising 
that any oral lesion lasting for more than two weeks, after local causative factors are 
removed, should be biopsied or referred without delay.193 
 
Most often, Australian oral cancer patients had one or more known risk factors for oral 
cancer at the time of diagnosis. This is similar to other cohorts from western nations where 
betel nut consumption is not prominent. Research that has already been conducted in the 
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USA and UK is likely to be relevant to our higher-risk target population. Australia is behind 
both the USA and UK and their respective oral cancer awareness month campaigns in 
promoting awareness for oral cancer and encouraging screening. 
 
Asymptomatic diagnosis of oral cancer at early stages of the disease is possible in the 
primary medical setting in Australia. Australian oral cancer patients are much more likely to 
see a GMP for other issues if they are asymptomatic with an oral lesion, indicating an 
opportunity for the GMP to suggest a visual and tactile oral cancer screening examination. 
They are also more likely to see a GMP than a GDP even if a symptomatic oral lesion is 
present, suggesting that interventions toward increasing oral cancer screening in Australia 
must be focused around the primary medical healthcare setting and GMPs.  
  
Current rates of visual and tactile oral cancer screening examination in Australia are very 
poor, and both GMPs and GDPs should be targeted to reach competency in diagnostic 
skill and performance of a thorough opportunistic screening examination of patients over 
40 who use tobacco products or drink alcohol regularly.  
  
 
 
42 
CHAPTER FOUR: AUSTRALIAN GMPs COMPARED TO GMSs 
 
4.1 Introduction 
Most oral cancers lack early symptoms; hence, by the time symptoms develop and 
stimulate a patient to seek a diagnosis, often the disease has already reached an 
advanced stage.13, 14 This results in more than 60% of patients being diagnosed with stage 
III or IV disease.13, 14 The reported five-year survival rate for stage III or IV oral cancer 
ranges between 15 and 55%.15-18 The most important prognostic marker for oral cancer 
remains the tumour stage at diagnosis.6, 12 Survival rates are significantly improved if the 
disease is treated at an early stage, ideally when the patient is likely to be asymptomatic 
with a tumour less than 2cm in diameter and with less than 4mm of invasion.20 Therefore, 
early detection of malignant lesions and OPMLs is an important goal for increasing the 
probability of improved morbidity and mortality.14, 15, 21, 22 
 
The Cochrane collaboration and other expert consortia have agreed that whilst population-
based annual or semi-annual screening for oral cancer is not cost-effective, targeting high-
risk populations to be opportunistically screened using a visual and tactile examination 
should be encouraged in the primary care setting.23-26 According to the WHO and the 
NIDCR, an oral cancer screening examination should include both visual and tactile 
components. The visual component requires examination of the face, neck, lips, labial 
mucosa, buccal mucosa, gingiva, floor of the mouth, tongue, and palate with mouth mirrors 
to help visualise all surfaces.30 The tactile examination includes palpating the regional 
lymph nodes, tongue, and floor of the mouth.30 Opportunistic oral cancer screening by 
GMPs and GDPs should remain an integral part of their routine daily work, and particular 
attention should be paid to high-risk individuals.27 The results from our study of Australian 
patients with oral cancer suggest, in line with the Cochrane collaboration, that the most 
significant risk factors in the development of oral cancer are increased age (over 40 years) 
and tobacco and alcohol consumption.28, 29 The increasing role of human papilloma virus 
(HPV) as an additional risk factor is consistent with the rising incidence of male and female 
HPV-related oral cancers in Australia and globally.91 
 
These known risk factors, and the relative ease of identifying oral cancers and OPMLs by 
a simple visual and tactile screening examination, point to significant potential for the 
prevention and early-state diagnosis of oral cancers. In theory, asymptomatic diagnosis at 
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an early stage of disease is achievable in the primary medical healthcare setting; however, 
the results from our cohort of patients with oral cancer indicate that very few opportunistic 
oral cancer screening examinations are actually being performed in Australia. 
Performance of an oral cancer screening examination requires either that the patient is 
sufficiently aware of oral cancer and his or her risk factors to request an oral cancer 
screening examination, or that the GMP or GDP is sufficiently aware of oral cancer and the 
patient’s risk factors to initiate a screening examination.  
 
The results from Chapter 3 highlight that patient awareness of oral cancer is very poor. 
Asymptomatic patients are therefore unlikely to attend a GMP or GDP and request oral 
cancer screening at the current level of awareness and knowledge. As discussed in 
Chapter 3, only 7% of the patients studied were diagnosed in the asymptomatic phase, 
and all of these by health practitioners with a dental qualification. This finding suggests 
that GDPs or specialists with dental qualifications were more active than GMPs in 
opportunistic oral cancer screening, a finding supported by a recent study of Australian 
GDPs which showed that 90% regularly perform oral mucosal screening examinations for 
all patients.31 Of the 93% of patients in our cohort who were diagnosed in the symptomatic 
phase, the majority preferred to attend a GMP (74%), rather than a GDP (14%), for 
investigation and explanation of their symptoms. This study also reported significant 
missed opportunities for oral cancer screening, as 80% of patients had seen their GMP 
within the last six months and 63% visited their GMP at least three times per year. Of 
concern is that whilst 84% of participants stated they have a regular GMP, only 3% of 
those GMPs had ever discussed risk factors for oral cancer and only 6% of the patients 
stated that their GMPs had ever performed an oral cancer screening examination on them.  
 
When awareness of oral cancer is compared between GMPs and GDPs, there is 
significant divergence in most populations studied. In a UK study, GMPs were less likely to 
examine patients' oral mucosa routinely, were less likely to advise patients about risk 
factors for oral cancer, and identified fewer risk factors for and felt less confident about 
diagnosing oral cancer from clinical appearance than their dental counterparts.168 A similar 
study in the USA concluded that GDPs were much more likely to feel adequately trained 
and regularly provide oral cancer screening examinations, but much less likely to discuss 
tobacco and alcohol cessation or to palpate the neck nodes.169 Additional studies in Saudi 
Arabia, Qazvin, Ireland, and Scotland have yielded similar results; some general 
conclusions were that GMPs are less intent on performing oral cancer screening, less 
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skilful in performing oral cancer screening examinations, and less confident in diagnosing 
pathologies in the oral cavity than GDPs.170-173 
 
These results were echoed by a comparison of UK undergraduate medical and dental 
students, which suggests that there will be no improvement in the next generation of 
health professionals, particularly medical practitioners, regarding oral cancer screening.176 
Further results along these lines from studies in Iran, Nigeria, and the USA indicate a need 
to review the curriculum of medical and dental schools to improve awareness and 
behaviour toward increasing opportunistic oral cancer screening.177-181 In 2011 two 
significant studies investigated medical school curricula for oral cancer teaching in the 
USA and UK, respectively. The majority of the responding USA medical schools offered 
very little oral health education, with approximately 80% offering less than five hours of 
oral health curriculum over the entire course.182 Oral cancer training lacked both adequacy 
and comprehensiveness, and showed no improvement relative to a similar study from 15 
years earlier.182, 183 The UK study highlighted that undergraduate oral cancer teaching 
varied widely in terms of duration, format, and content across British medical schools.184 
Its authors recommended the development of a curriculum addressing important aspects 
of oral cancer from an evidence-based approach that can be integrated into the already-
crowded undergraduate medical curriculum.184 
 
There are no data on the awareness, knowledge, and attitudes toward opportunistic oral 
cancer screening in the Australian GMP population. Similarly, there is no Australian study 
investigating these same attributes in graduate medical students as they exit medical 
school and enter the workforce. The primary purpose of the following research is to 
establish this Australian dataset via a survey of new GMSs and established practicing 
GMPs in Brisbane. It is hoped that this dataset will provide valuable insights leading to 
educational and training interventions, and thereby improve the rates of visual and tactile 
opportunistic oral cancer screening in the primary medical healthcare setting in Australia. 
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4.2 Hypotheses 
1. Both groups do not routinely examine oral mucosa. 
2. Both groups have received limited education and training in oral cancer and 
visual and tactile oral cancer screening examination  
3. Both groups do not routinely advise patients about risk factors for oral cancer. 
4. Both groups are not confident diagnosing malignant and pre-malignant lesions 
from clinical appearance. 
5. Both groups do not perform all nine steps of a visual and tactile oral cancer 
screening examination. 
6. Both groups are not sufficiently confident in their techniques to complete all 
nine steps of a visual and tactile oral cancer screening examination. 
7. Both groups are not confident in identifying pathology in all nine steps of a 
visual and tactile oral cancer screening examination. 
 
4.3 Aims 
This study aims to identify: 
1.  whether either group routinely examines oral mucosa; 
2. whether either group had sufficient training in oral cancer and visual and tactile 
oral cancer screening examination; 
3. whether either group knows the risk factors and communicates these to 
patients; 
4. what changes in the oral mucosa both groups would associate with malignant 
and pre-malignant oral lesions; 
5.  which of the nine steps of the visual and tactile oral cancer screening 
examination are performed by either group; 
6. whether either group is confident in performing the technique in each of the 
nine steps of the visual and tactile oral cancer screening examination; 
7. whether either group is confident in identifying pathology in each of the nine 
steps of the visual and tactile oral cancer screening examination; and 
8.  where patients are referred if an oral cancer or OPML is identified. 
  
 
 
46 
 
4.4 Methods and Materials 
 
Ethical Approvals 
The study protocol was approved by the University of Queensland Dental Science 
Research Ethics Committee (1217) and the RBWH Human Research Ethics Committee 
(HREC/14/QRBW/82). 
 
Study Design 
Following a literature review that investigated similar issues in populations of graduate 
medical students (GMS) and general medical practitioners (GMPs) in other locations 
worldwide, a questionnaire was designed and validated with a pilot group of GMPs and 
GMSs utilising the test and re-test method.168, 176 553 GMPs were selected randomly for 
the sample from a database developed on GMPs working in locations that would be 
expected to refer suspected oral cancer patients to the RBWH Head and Neck Clinic. A 
similar questionnaire was designed to collect data from a sample of 151 Graduate Medical 
Students (GMS) commencing work as intern medical officers at the RBWH in Brisbane, 
Australia.  
 
Participant Recruitment 
Each research study pack contained an introductory cover letter on Queensland Health 
letterhead signed by the site coordinator, a participant information form, a participant 
informed consent form, the questionnaire, and a professionally addressed and stamped 
envelope for return of the questionnaire. These packs were mailed, utilising the modified 
Dillman method known to increase response rates, to those GMPs randomly selected by 
practice address within the catchment of referral to the RBWH Head and Neck Clinic.31, 187-
189 The GMSs were invited to participate during intern training days on commencement 
with Queensland Health, and were able either to consent to, complete, and return the 
questionnaire at this training meeting, or to return the questionnaire via pre-paid mail. The 
questionnaire responses were initially identifiable to allow a follow-up phone call for 
clarification of responses if required and to award the incentive (“the new iPad”), which 
was randomly drawn by the chief investigator at the conclusion of data collection. 
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Questionnaires 
The GMP questionnaire consisted of 49 open, multiple-choice, or closed questions 
investigating the stated aims of the study. The GMS questionnaire asked an additional four 
questions to investigate GMS exposure to OPMLs, oral cancers, learning regarding oral 
cancer, and appropriate screening during medical school. The full copy of the 
questionnaire given to GMPs is available in Appendix B. The full copy of the questionnaire 
given to GMSs is available in Appendix C. 
 
Data Analysis 
Completed questionnaires were de-identified, manually coded and recorded into Microsoft 
Excel (Microsoft Corporation, Washington, USA) to allow statistical analysis of binary and 
non-binary responses. The results were expressed as proportions and frequency count 
charts calculated using Microsoft Excel (Microsoft Corporation, Washington, USA) When 
comparing responses between groups, Pearson’s Chi-Squared Test was calculated using 
Stata (Statacorp, Texas, USA) and differences were considered statistically significant at a 
p-value of < 0.05. 
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4.5 Research Results 
Unless otherwise stated, all percentages reported are the percentage in agreement. 
 
4.5.1 Survey Response Rate and Demographics 
Questionnaires were returned by 144 GMPs and 141 GMSs, a response rate of 27% and 
93% respectively. The proportions of male and female participants were comparable. The 
majority of GMPs (83%) had graduated from medical school over 15 years ago, in 
comparison to all GMSs, who had just entered the work force out of medical school. Table 
4.1 displays the response rates and demographics collected. 
 
Table 4.1: Survey Response and Demographics 
 GMPs GMSs 
Total Surveyed 553 151 
Total Responses 144 141 
Response Rate 27% 93% 
Male 71 (49%) 66 (47%) 
Female 73 (51%) 75 (53%) 
Years Since Graduation  
                 < 15 24 (17%) 141 (100%) 
                15-29 51 (35%) 0 (0%) 
                30-45 62 (43%) 0 (0%) 
                45+ 7 (5%) 0 (0%) 
 
4.5.2 Awareness, Behaviours and Training in Oral Cancer 
Table 4.2 summarises the responses to questions regarding awareness of oral cancer, 
undergraduate and postgraduate teaching on the examination of the oral cavity, and 
diagnosis of pre-malignant and malignant disease. Over 90% of both groups reported 
regularly advising patients about risk factors for other cancers and encouraging risk 
reduction for these; however, only a third of both groups regularly advised patients about 
risk factors for oral cancer. GMPs reported significantly more knowledge than GMSs 
(44%vs18%, p < 0.001) regarding prevention of oral cancer, but less than 50% of both 
groups reported performing oral cancer screening examinations, even on high-risk 
patients. After reading the nine steps of a visual and tactile oral cancer screening 
examination that were displayed and explained in the questionnaire, only 34% of GMPs 
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and 11% of GMSs felt they had sufficient knowledge to detect a pre-malignant lesion or an 
early asymptomatic oral cancer. About one-fifth of both GMPs and GMSs stated they had 
received sufficient training during either GP training or medical school to identify high-risk 
groups and perform thorough opportunistic oral cancer screening examinations. 
 
Table 4.2: Awareness and Knowledge for Oral Cancer (GMPs vs. GMSs) 
(# - GMPs not asked this question) GMPs 
n=144 
GMSs 
n=141 
𝛘 2 p-value  
Have you had an oral cancer screening examination 
performed on yourself? 
27 (19%) 12 (9%)    0.013* 
Have you ever seen an oral cancer during medical 
school?# 
# # 65 (46%)  
Have you ever seen a pre-malignant oral lesion during 
medical school?# 
# # 55 (39%)  
Did you learn about oral cancer during medical 
school?# 
# # 104 (74%)  
Did you learn about opportunistic oral cancer screening 
during medical school?# 
# # 15 (11%)  
Do you regularly advise patients about risk factors for 
other cancers? 
139 (97%) 129 (92%)    0.109 
Do you regularly encourage reduction in risk factors for 
other cancers 
143 (99%) 135 (96%)    0.052 
Do you regularly advise patients about risk factors for 
oral cancer? 
46 (32%) 48 (34%)    0.675 
Do you feel you have sufficient knowledge concerning 
prevention of oral cancer? 
64 (44%) 25 (18%)    <0.001** 
Do you perform oral cancer screening routinely? 9 (6%) 30 (22%)    <0.001** 
If not routinely, do you perform oral cancer screening if 
patients are in high-risk groups? 
64 (47%) 46 (42%)    0.417 
Do you have sufficient training, knowledge and 
technique to perform oral cancer screening 
examination? 
 (Before screening examination steps shown) 
46 (32%) 10 (7%)    <0.001** 
Do you feel you have sufficient knowledge to detect a 
pre-malignant lesion or an early asymptomatic oral 
cancer? 
(After screening examination steps shown) 
49 (34%) 15 (11%)    <0.001** 
Do you feel you received sufficient training in either GP 
training or medical school to identify high-risk groups 
and perform thorough opportunistic oral cancer 
screening examinations? 
(After screening examination steps shown) 
29  (20%) 27 (19%)    0.833 
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4.5.3 Knowledge of Risk Factors for Oral Cancer 
Table 4.3 presents the responses to the open text question asking both groups to list as 
many risk factors for oral cancer as they could recall. Both groups strongly identified 
tobacco as a risk factor. Approximately half of each group (GMPs 57%, GMS 54%) 
identified alcohol as a risk factor. Other known risk factors, such as age, HPV infection, 
areca nut (betel nut) chewing, and poor diet were not identified strongly by either group. 
Overall, when the groups were compared regarding knowledge of the main risk factors for 
oral cancer (age, tobacco, alcohol, betel nut chewing, HPV status, and poor diet), there 
was no significant difference between the inexperienced GMSs and experienced GMPs. 
 
Table 4.3: Knowledge of Risk Factors for Oral Cancer (GMPs vs. GMSs) 
 
4.5.4 Knowledge of Pre-Malignant and Malignant Clinical Changes 
Table 4.4 presents the responses to open text questions regarding knowledge of clinical 
changes in pre-malignancy and oral malignancy. In regard to pre-malignancy, both groups 
identified, in rank order: leukoplakia, non-healing lesions, and lump/swelling/induration. In 
regard to oral malignancy, GMPs identified, in rank order: non-healing lesions, 
lump/swelling/induration, and leukoplakia. The GMSs were similar, with 
lump/swelling/induration and non-healing lesions, followed by bleeding. Overall, neither 
 GMPs GMSs    𝛘 2 p-value  
Age 19 (13%) 21 (15%) 0.626 
Alcohol  82 (57%) 75 (54%) 0.661 
Betel Nut  31 (22%) 24 (17%) 0.381 
Ethnicity 5 (3%) 5 (10%) 0.072 
Family History 21 (15%) 47 (34%) < 0.001 ** 
HIV/Immunosuppression 23 (16%) 26 (19%) 0.525 
HPV 29 (20%) 37 (27%) 0.186 
Male Gender  3 (2%) 4 (8%) 0.049 * 
Oral Sex 0 (0%) 10 (7%)  
Oral Pre-Malignant Lesion  16 (11%) 1 (2%) 0.050 * 
Poor Dental Hygiene/Chronic Irritation 34 (24%) 23 (17%) 0.147 
Poor Diet 4 (3%) 7 (5%) 0.320 
Previous Head and Neck Cancer 17 (12%) 42 (30%) < 0.001 ** 
Tobacco 144 (100%) 134 (97%) 0.040 * 
UV/Radiation 24 (17%) 4 (8%) 0.129 
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group was confident in diagnosing pre-malignant and malignant lesions from clinical 
appearance, but GMPs were significantly more confident than GMSs (GMPs 53% vs. 
GMSs 88%, p<0.001). 
Table 4.4: Knowledge of Pre-malignant and Malignant Clinical Changes 
 
 
  
 GMPs GMSs 
   𝛘 2 p-value  
 
What changes in oral cavity would you associate with pre-malignant disease? 
(Open Text Responses Grouped As Follows) 
Leukoplakia 116 (82%) 81 (60%) <0.001** 
Erythroleukoplakia 11 (8%) 3 (6%) 0.595 
Erythroplakia 24 (17%) 10 (19%) 0.747 
Non-Healing Lesions (Ulcer/OLP)  88 (62%) 54 (41%) <0.001** 
Lumps/Swelling/Induration 51 (36%) 52 (39%) 0.586 
Pain/Dysphagia/Hypo/Hyperaesthesia 10 (7%) 4 (3%) 0.125  
Pigmentation  19 (13%) 8 (15%) 0.795 
Bleeding 12 (8%) 14 (11%) 0.557 
What changes in oral cavity would you associate with malignant disease? 
(Open Text Responses Grouped As Follows) 
Leukoplakia 42 (30%) 33 (25%) 0.355 
Erythroleukoplakia 6 (4%) 0 (0%)   
Erythroplakia 10 (7%) 5 (10%) 0.552 
Non Healing Lesions (Ulcer/OLP)  122 (86%) 71 (53%) < 0.001** 
Lumps/Swelling/Induration 108 (76%) 95 (71%) <0.001** 
Pain/Dysphagia/Hypo-/Hyper-aesthesia 19 (13%) 15 (11%) 0.581 
Pigmentation  12 (8%) 24 (18%) 0.020* 
Bleeding 27 (19%) 38 (28%) 0.067 
Dental Hygiene/Odour 0 (0%) 9 (7%)  
In regard to clinical appearance, do you feel confident diagnosing pre-malignant 
and malignant lesions from clinical appearance?  
<0.001** 
Very Confident 4 (3%) 0 (%)  
Confident 63 (44%) 16 (12%)  
Not Confident 71 (50%) 102 (74%)  
Very Not Confident 5 (3%) 20 (14%)  
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4.5.5 Nine-Step Oral Cancer Screening Examination 
The section presents results in relation to questions about performing each step of the 
recommended nine-step visual and tactile oral cancer screening examination. Table 4.5 
presents the results of assessing whether the recommended equipment is accessible to 
the GMP or GMS in their clinical setting; that is, whether there are equipment barriers to 
performing opportunistic screening examinations. The main barrier appears to be poor 
access to dental or ENT mirrors. 
 
Table 4.5: Tools Required for Oral Cancer Screening Examination  
 
 
Tables 4.7, 4.8, and 4.9 report the results for each step of the screening examination, 
asking whether the step is performed and assessing confidence with the technique of the 
required examination step and confidence in identifying pathology in that specific step. 
Each step on the questionnaire contained a picture of the step and an explanation in text 
of the technique involved. The GMPs indicated that, in their routine, the only steps 
performed more often than not were Step 1 (extra-oral), Step 2 (lip examination), and Step 
8 (palate and oro-pharynx). The GMSs had even fewer steps in their routine, with only 
Step 1 (extra-oral) performed more often than not. Confidence in performing the step for 
both groups mirrored whether they actually performed the step in their routine. It follows 
that in all other steps, neither group was confident performing the technique required. 
Likewise, confidence in identifying pathology mirrored whether they actually performed the 
step. In all steps other than Step 1 (extra-oral), GMSs were significantly less confident in 
the technique and pathology identification than the GMPs. Table 4.6 highlights the poor 
overall proficiency of each group, with GMPs performing 4.3 steps on average compared 
to 3.8 for GMSs. Overall, while GMSs were significantly worse than the GMPs, neither 
group was confident with techniques and pathology identification in the screening 
examination. 
  
Do you have all the equipment required to 
perform an oral cancer screening 
examination? (% in agreement) 
GMPs GMSs    𝛘 2 p-value  
Bright White Light Source 138 (96%) 56 (53%) < 0.001 ** 
Dental or ENT Mirror 29 (20%) 7 (7%) 0.003 * 
Gauze Squares  133 (92%) 116 (93%) 0.891  
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Table 4.6: Summary of Proficiency in Oral Cancer Screening Examination 
Average number of steps (standard deviation)                    GMP GMS 𝛘 2 p-value 
Performed 4.3 (2.3) 3.8 (2.4) 0.075 
Confident with technique 4.6 (2.6) 2.9 (2.3) < 0.001 *** 
Confident with identifying pathology 4.2 (2.8) 2.2 (2.4) < 0.001 *** 
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Table 4.7: Oral Cancer Screening Steps 1-3  
Performed, Confidence in Technique, and Confidence in Pathology Identification 
Step 1: Extra-oral examination GMP  GMS  𝛘 2 p-value  
Perform 130 (90%) 129 (91%) 0.722 
Do not perform 14 (10%) 12 (9%)  
How confident are you with your technique of extra-oral 
examination? 
    
Very Confident 24 (17%) 19 (14%) 0.079 
Confident 107 (74%) 95 (68%)  
Not Confident 12 (8%) 25 (18%)  
Very Not Confident 1 (1%) 0 (%)  
How confident are you with identifying pathology in extra-oral 
examination? 
    
Very Confident 19 (13%) 1 (1%) < 0.001 *** 
Confident 102 (71%) 78 (56%)  
Not Confident 23 (16%) 50 (36%)  
Very Not Confident 0 (%) 10 (7%)  
Step 2: Lip Examination GMP  GMS  𝛘 2 p-value 
Perform 117 (81%) 65 (46%) < 0.001 *** 
Do not perform 27 (19%) 76 (54%)  
How confident are you with your technique of lip examination?     
Very Confident 23 (16%) 1 (1%) < 0.001 *** 
Confident 97 (67%) 58 (41%)  
Not Confident 22 (15%) 70 (50%)  
Very Not Confident 2 (1%) 12 (9%)  
How confident are you with identifying pathology in lip 
examination? 
    
Very Confident 17 (12%) 1 (1%) < 0.001 *** 
Confident 91 (63%) 44 (31%)  
Not confident 35 (24%) 84 (60%)  
Very Not Confident 1 (1%) 12 (9%)  
Step 3: Labial Mucosa Examination GMP  GMS  𝛘 2 p-value  
Perform 55 (38%) 38 (28%) 0.057 
Do not perform 89 (62%) 100 (72%)  
How confident are you with your technique of labial mucosa 
examination? 
    
Very Confident 5 (3%) 1 (1%) 0.017 * 
Confident 56 (39%) 36 (26%)  
Not Confident 77 (53%) 88 (64%)  
Very Not Confident 6 (4%) 13 (9%)  
How confident are you with identifying pathology of the labial 
mucosa? 
    
Very Confident 6 (4%) 1 (1%) 0.002 * 
Confident 49 (34%) 24 (18%)  
Not Confidant 84 (58%) 102 (74%)  
Very Not Confident 5 (3%) 10 (7%)  
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Table 4.8: Oral Cancer Screening Steps 4-6  
Performed, Confidence in Technique, and Confidence in Pathology Identification 
Step 4: Buccal Mucosa Examination GMP  GMS  𝛘 2 p-value  
Perform 35 (24%) 45 (32%) 0.132 
Do not perform 109 (76%) 94 (68%)  
How confident are you with your technique of buccal mucosa 
examination? 
    
Very Confident 2 (1%) 0 (%) 0.014 * 
Confident 47 (33%) 25 (18%)  
Not Confident 80 (56%) 99 (71%)  
Very Not Confident 15 (10%) 15 (11%)  
How confident are you with identifying pathology of the buccal 
mucosa? 
    
Very Confident 4 (3%) 0 (%) 0.008 * 
Confident 44 (31%) 24 (17%)  
Not Confident 84 (58%) 103 (74%)  
Very Not Confident 12 (8%) 12 (9%)  
Step 5: Gingival Examination GMP  GMS  𝛘 2 p-value  
Perform 51 (35%) 50 (36%) 0.958 
Do not perform 93 (65%) 90 (64%)  
How confident are you with your technique of gingival examination?     
Very Confident 3 (2%) 0 (%) 0.039 * 
Confident 50 (35%) 32 (23%)  
Not Confident 81 (56%) 97 (69%)  
Very Not Confident 10 (7%) 11 (8%)  
How confident are you with identifying pathology of the gingiva?     
Very Confident 3 (2%) 0 (%) 0.028 * 
Confident 43 (30%) 25 (18%)  
Not Confident 87 (60%) 103 (74%)  
Very Not Confident 11 (8%) 12 (9%)  
Step 6: Tongue Examination GMP  GMS    𝛘 2 p-value 
Perform 48 (33%) 73 (52%) 0.002 * 
Do not perform 96 (67%) 68 (48%)  
 How confident are you with your technique of tongue examination?     
Very Confident 4 (3%) 0 (%) 0.114 
Confident 65 (45%) 54 (38%)  
Not Confident 68 (47%) 80 (57%)  
Very Not Confident 7 (5%) 7 (5%)  
How confident are you with identifying pathology of the tongue?     
Very Confident 4 (3%) 0 (%) 0.025 * 
Confident 63 (44%) 45 (32%)  
Not Confident 67 (47%) 86 (61%)  
Very Not Confident 10 (7%) 10 (7%)  
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Table 4.9: Oral Cancer Screening Steps 7-9 
Performed, Confidence in Technique, and Confidence in Pathology Identification 
Step 7:  Ventral Tongue and Floor of Mouth GMP  GMS    𝛘 2 p-value  
Perform 62 (43%) 52 (37%) 0.309 
Do not perform 82 (57%) 88 (63%)  
How confident are you with your technique of floor of mouth 
examination? 
    
Very Confident 4 (3%) 0 (%) 0.002 * 
Confident 59 (41%) 34 (24%)  
Not Confident 75 (52%) 96 (68%)  
Very Not Confident 6 (4%) 11 (8%)  
How confident are you with identifying pathology of the floor of 
mouth? 
    
Very Confident 4 (3%) 0 (%) 0.001 * 
Confident 49 (34%) 24 (17%)  
Not Confident 84 (58%) 103 (74%)  
Very Not Confident 7 (5%) 13 (9%)  
Step 8: Palate and Oro-pharynx GMP  GMS  𝛘 2 p-value  
Perform 80 (56%) 62 (44%) 0.058 
Do not perform 64 (44%) 78 (56%)  
How confident are you with your technique of tongue examination?     
Very Confident 3 (2%) 0 (%) < 0.001 *** 
Confident 71 (49%) 43 (30%)  
Not Confident 66 (46%) 86 (61%)  
Very Not Confident 4 (3%) 12 (9%)  
How confident are you with identifying pathology of the tongue?     
Very Confident 4 (3%) 0 (%) < 0.001 *** 
Confident 60 (42%) 30 (21%)  
Not Confident 76 (53%) 100 (71%)  
Very Not Confident 4 (3%) 11 (8%)  
Step 9: Bimanual palpation of Floor of Mouth GMP  GMS  𝛘 2 p-value  
Perform 39 (27%) 20 (14%) 0.008 * 
Do not perform 105 (73%) 120 (86%)  
How confident are you with your technique of bimanual palpation?     
Very Confident 4 (3%) 0 (%) < 0.001 *** 
Confident 38 (27%) 6 (4%)  
Not Confident 89 (62%) 96 (69%)  
Very Not Confident 12 (8%) 38 (27%)  
How confident are you with identifying pathology using this method 
of palpation? 
    
Very Confident 3 (2%) 0 (%) < 0.001 *** 
Confident 34 (24%) 8 (6%)  
Not Confident 91 (64%) 92 (66%)  
Very Not Confident 15 (10%) 40 (29%)  
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4.5.6 Referral Destination for Pre-Malignant and Malignant Lesions 
Table 4.10 presents the responses to questions regarding referral destination. Participants 
could select more than one destination if desired. The groups were similar in responses, 
with the referral destination most likely to be oral and maxillofacial surgeons, followed by 
ear, nose, and throat (ENT) surgeons and oral medicine/oral pathologist, irrespective of 
suspected pre-malignancy or malignancy in the oral cavity. 
 
Table 4.10: Referral Destination for Pre-Malignant and Malignant Lesions 
 
  
Where would you refer a patient if you suspected 
a pre-malignant lesion in oral cavity? 
GP (n=144) Student (n=141) 
Oral and Maxillofacial Surgeon 86 (60%) 81 (57%) 
ENT Surgeon 69 (48%) 51 (36%) 
Oral Medicine/Oral Pathologist 23 (16%) 9 (6%) 
Dentist 15 (10%) 8 (6%) 
Plastic Surgeon 5 (3%) 2 (1%) 
No Referral (manage by self) 3 (2%) 0 (0%) 
RBWH Head and Neck Clinic 1 (1%) 0 (0%) 
Where would you refer a patient if you suspected 
a malignant lesion in oral cavity? 
GP (n=144) Student (n=141) 
Oral and Maxillofacial Surgeon 103 (72%) 86 (61%) 
ENT Surgeon 65 (45%) 50 (35%) 
Oral Medicine/Oral Pathologist 10 (7%) 7 (5%) 
Plastic Surgeon 3 (2%) 7 (5%) 
RBWH - Head & Neck Clinic 1 (1%) 1 (1%) 
Dentist 1 (1%) 0 (0%) 
Other (specify) 0 (0%) 1 (1%) 
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4.6 Discussion 
There is significant potential for prevention and early-stage diagnosis of oral cancers 
because their risk factors are known and it is relatively easy to identify them via a simple 
visual and tactile oral cancer screening examination. The results from our Australian 
cohort of oral cancer patients in Chapter 3 indicate that very few opportunistic oral cancer 
screening examinations are being performed in the high-risk population in Australia. Only 
7% of the patients studied were diagnosed in the asymptomatic phase, and these were all 
by health practitioners with a dental qualification. Of the 93% of patients studied in our 
cohort who were diagnosed in the symptomatic phase, the majority preferred to attend a 
GMP, rather than a GDP, for investigation and explanation of their symptoms. The study 
also highlighted significant missed opportunities for oral cancer screening, as the majority 
of patients visited their GMP regularly but fewer than 10% had ever received an oral 
cancer screening examination or discussion of risk factors.  
 
Previous studies have shown that GMPs are more likely to see the high-risk target 
population for oral cancer than their dental counterparts.194 Of concern is that while 84% of 
the oral cancer participants had a regular GMP, only 3% of those GMPs had ever 
discussed the risk factors for oral cancer, and only 6% of patients had an oral cancer 
screening examination performed on them by the GMP. The importance of GMP 
awareness of oral cancer, knowledge of the risk factors, ability to competently perform a 
visual and tactile oral cancer screening examination, and confidence in identifying 
pathology during that examination should not be underestimated. Likewise a GMS entering 
the workforce should be aware, knowledgeable, and confident in identifying a high-risk 
individual, suggesting and performing an opportunistic oral cancer screening examination.  
 
Our first study aim in this chapter was to identify whether either group routinely examines 
oral mucosa. Our finding that 6% of GMPs routinely perform oral cancer screening (Table 
4.2) is surprisingly consistent with the 6% of oral cancer patients that reported ever being 
screened for oral cancer by their GMP. 22% of GMSs reported performing oral cancer 
screening routinely; however, when asked if they would do so for a high-risk patient, the 
responses of both groups increased to over 40%, suggesting that they had some 
awareness of high-risk populations and a willingness to perform the screening examination 
in the medical healthcare setting. 
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Unfortunately, our second study aim identified that both groups had insufficient training in 
oral cancer and performing the visual and tactile oral cancer screening examination. GMSs 
were asked four additional questions relating to their recent medical school experience. 
74% had learnt about oral cancer in medical school and almost half (46%) had seen an 
oral cancer, yet only 11% recalled ever learning about opportunistic oral cancer screening. 
Initially about one-third of GMPs reported that they had sufficient training, knowledge, and 
technique to perform oral cancer screening. Whilst over 40% of both groups initially stated 
that they would screen if the patient was high-risk, once the nine steps of a screening 
examination were shown in the next part of the questionnaire, only 20% of both groups felt 
they had sufficient training to identify a high-risk patient and perform a thorough 
opportunistic nine-step screening examination.  
 
Our third study aim was to identify whether either group knew the risk factors for oral 
cancer and communicated these to patients. We found no statistically significant difference 
between the groups with regard to their knowledge of the main risk factors for oral cancer 
(Table 4.3). Both groups strongly identified tobacco as a risk factor, consistent with studies 
from both developed and developing countries.168, 176, 195-197 Approximately half of each 
group (GMPs 57%, GMS 54%) identified alcohol as a risk factor, again consistent with 
other studies reporting a less well-known association of oral cancer with alcohol 
consumption.198 Other known risk factors, such as age, HPV, betel nuts, and poor diet, 
were not identified strongly by either group. The evidence for the role of HPV as an 
aetiologic agent in oral cancer has grown rapidly, and two recent meta-analyses found 
HPV to be an independent risk factor for a subset of oral cancers.81, 82 More than 70% of 
the participants in the present study did not list HPV as a risk factor, similar to reported 
findings in other studies.195, 198 Most GMPs (97%) regularly advised patients about risk 
factors for other cancers, and nearly all GMPs (99%) regularly encouraged risk factor 
reduction for other cancers. 32% of GMPs self-reported advising patients about their risk 
factors for oral cancer, which contradicts the 3% figure generated by the oral cancer 
patient cohort when asked if a GMP had ever discussed their risk factors for oral cancer 
with them. These findings suggest that Australian GMPs and GMSs are deficient in 
knowledge regarding risk factors for oral cancer, which is likely to limit their ability to 
identify at-risk patients and perform opportunistic screening. 
 
The fourth aim for this study was to identify what changes in the oral mucosa both groups 
would associate with malignant and pre-malignant oral lesions, via responses to open text 
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questions regarding knowledge of clinical changes in pre-malignancy and oral malignancy 
(Table 4.4). With regard to pre-malignancy, both groups identified leukoplakia, non-healing 
lesions, and lump/swelling/induration, in that order. Unfortunately, this shows a poor 
understanding of the clinical appearance of OPMLs, a collective term used for the wide 
range of clinical presentations of oral lesions that may harbour oral epithelial dysplasia 
(OED). Clinically OPMLs can appear as leukoplakia, erythroplakia, or erythro-leukoplakia 
(speckled erythroplakia).22 Although various other factors, such as smoking history, patient 
age and gender, and lesion size and location may contribute to the suspicion of malignant 
potential, clinical appearance is often the primary driving factor toward the decision to 
biopsy or offer intervention.35   
 
Clinical leukoplakias, the most common OPMLs, show a low rate of malignant progression 
irrespective of the histopathologic diagnosis of mild, moderate, or severe dysplasia.36  In 
contrast, erythroplakias and erythro-leukoplakias have been shown to have a much higher 
risk of malignant transformation (14-50%).37 We can confidently state that lesions 
exhibiting redness or a non-homogenous texture were strongly associated with OED and 
should be considered for biopsy at presentation.38-40 Unfortunately, these clinical features 
at presentation may allow estimation of the rate of OED in OPMLs, but there is no way of 
differentiating OPMLs into dysplastic and non-dysplastic on clinical findings alone, 
because OED can manifest clinically in any number of presentations.42-44 
 
With regard to changes related to malignant disease, 86% of GMPs correctly identified 
non-healing lesions as suspicious. A significant proportion of GMPs (30%) and GMSs 
(25%) reported leukoplakia as a clinical change associated with malignancy. Most often 
these leukoplakia are not homogenous. Malignancy can present as 
lumps/swelling/induration, be painful or painless, be pigmented, or bleed. Overall both 
groups reported being ‘not confident’ in diagnosing pre-malignant and malignant lesions 
from clinic appearance (GMPs 53% vs. GMSs 88%, p<0.001). This p-value indicates that 
GMPs are significantly more confident than GMSs. It appears necessary to improve 
teaching on OPMLs and oral malignancy in the undergraduate medical curriculum and 
provide continuing medical education opportunities for GMPs to improve current 
deficiencies in knowledge of oral cancer. The key message for both groups is that any oral 
lesion lasting longer than 2 weeks, after local possible causative factors are removed, 
should be biopsied or referred without delay.199 GMPs and GMSs should also be educated 
 
 
61 
to look for leukoplakia, erythroplakia, and erythroleukoplakia during the oral cancer 
screening examination. 
 
The next three aims of our study all relate to the nine steps of the visual and tactile oral 
cancer screening examination specified by the WHO and NIDCR.30 The first objective was 
to identify which of the nine steps of the visual and tactile oral cancer screening 
examination either group performed. When individual steps were assessed, GMPs 
indicated that the only steps performed more often than not (meaning over 50% of GMPs 
indicated that they did perform the step) were Step 1 (extra-oral), Step 2 (lip examination) 
and Step 8 (palate and oro-pharynx). The GMSs had even fewer steps in their routine, with 
only Step 1 (extra-oral) performed more often than not. When the nine steps were 
assessed together, each group exhibited poor overall efficiency (Table 4.6), with GMPs 
performing 4.3 steps on average compared to 3.8 for GMSs. Of most concern is that both 
groups often overlooked common sites of oral cancer development, such as the floor of 
the mouth, venterolateral surface of the tongue, and retromolar trigone. The second and 
third objectives were to identify whether either group was confident in performing the 
technique of each step and identifying pathology at each step. Confidence in performing 
each step for both groups mirrored whether they actually performed the step more often 
than not, with GMPs confident in performing Steps 1, 2, and 8, and GMSs only Step 1. In 
all other steps neither group was confident performing the technique required. Likewise, 
confidence in identifying pathology for each group mirrored performance of the step; in all 
steps except Step 1(extra-oral), GMSs were statistically significantly less confident in the 
technique and identifying pathology than the GMPs (Table 4.6). 
 
The results of this study clearly indicate that GMPs in Australia lack the awareness, 
knowledge, equipment, and skills to adequately perform opportunistic screening for oral 
cancer in high-risk patients attending their practice. When these results are compared to 
other results from similar studies across the world, Australian GMPs are similar to their 
peers in the developed nations. GMPs are unlikely to examine patient’s oral mucosa 
routinely, unlikely to advise patients about risk factors for oral cancer, likely to identify few 
risk factors, technically poor at performing the nine steps of oral cancer screening 
examinations, and overall not confident in diagnosing OPMLs or oral cancers.168-173 In 
addition, medical students entering the workforce have been trained with even less 
awareness, knowledge, confidence, and skills for performing opportunistic screening for 
oral cancer than their more experienced colleagues.   
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Intent of GMPs to conduct oral cancer screening has been investigated utilising the Theory 
of Planned Behaviour, and this has identified barriers to conducting oral examinations for 
screening purposes in general medical practice. The results suggest that there is 
considerable potential for improving intention to perform oral cancer screening in general 
practice.174 Suggested interventions include: 1) theory-based interventions, such as further 
training to enhance confidence, expertise, knowledge, and ease of examination, 2) 
provision of adequate equipment in the surgery (light and dental mirrors), and 3) 
introducing guidelines on opportunistic screening that increase motivation to comply with 
goals, such as more peers performing screening or an oral cancer awareness month.174  
One potential threat to improving opportunistic screening amongst GMPs was identified in 
a Scottish study that reported a high proportion of GMPs (66%) felt strongly that oral 
cancer detection is the remit of the dental team.172 If this same opinion pervades the 
GMPs in Australia, then it may prove difficult to change behaviour regarding opportunistic 
screening. At present the RACGP teaches that there is insufficient evidence to 
recommend screening by visual inspection or by other screening methods.175 The RACGP 
identifies increased-risk individuals as smokers aged greater than 50 years, heavy 
drinkers, patients chewing tobacco or areca/betel nuts, and those exposed to excessive 
UV in the lip area.175  If an individual is identified as increased risk, the RACGP 
encourages opportunistic examination of mouth and lips every 12 months but does not 
provide an examination description matching the desired nine-step visual and tactile oral 
cancer screening examination.30, 175 
 
With regard to GMP skill in performing an oral cancer screening examination, there is a 
statistically significant association between undergraduate and postgraduate teaching on 
examination of the oral cavity and whether practitioners felt confident in their ability to 
detect oral cancer.173 GMPs also display decreased diagnostic confidence in detecting 
malignancies or OPMLs. In fact, in a study of Irish GMPs, a statistically significant 
association was found between undergraduate and postgraduate teaching on the 
diagnosis of oral malignant disease and whether practitioners felt confident in their ability 
to detect oral cancer and OPMLs clinically.173 The authors concluded that the knowledge 
level of GMPs needs improvement with appropriate initiatives at both the undergraduate 
and graduate levels via continued medical education (CME).173 CME is encouraged 
worldwide for healthcare professionals and is compulsory in Australia. Internet-based CME 
programmes have demonstrated that they are also an effective medium for transfer of 
 
 
63 
knowledge for health care practitioners.200 Engaging with GMP training colleges, such as 
the RACGP in Australia, may be of benefit for review of the postgraduate training 
curriculum and updating of guidelines regarding prevention and early detection of oral 
cancer. The question of what is being taught at medical schools across Australia in relation 
to oral cancer also remains. The GMS results point to a need to develop an undergraduate 
curriculum to address the important aspects of oral cancer from an evidence-based 
approach that can be integrated into the already crowded undergraduate medical 
curriculum.184   
 
Table 4.11: Hypotheses Results (GMPs vs. GMSs) 
Hypotheses Tested 
 
Outcome 
GMPs vs GMSs  (p-value) 
Both groups do not routinely examine oral mucosa. Null hypothesis true 
6% vs 22% (<.001***) 
 
Both groups have received limited education and 
training in oral cancer and visual and tactile oral 
cancer screening examination  
 
Null hypothesis true 
20% vs 19% (0.833) 
Both groups do not routinely advise patients about risk 
factors for oral cancer. 
 
Null hypothesis true  
32% vs 34% (0.675) 
 
Both groups are not confident diagnosing malignant 
and pre-malignant lesions from clinical appearance. 
 
Null hypothesis true 
53% vs 88% (<0.001***) 
Both groups do not perform all nine steps of a visual 
and tactile oral cancer screening examination. 
 
Null hypothesis true 
Average steps performed 
4.3 vs 3.8 (0.075) 
 
Both groups are not sufficiently confident in their 
techniques to complete all nine steps of a visual and 
tactile oral cancer screening examination. 
 
Null hypothesis true 
Average steps confident in technique 
4.6 vs 2.9 (<0.001***) 
Both groups are not confident in identifying pathology 
in all nine steps of a visual and tactile oral cancer 
screening examination. 
Null hypothesis true 
Average steps confident in pathology 
4.2 vs 2.2 (<0.001***) 
 
In summary, Table 4.11 presents a tabulated summary of outcomes to the seven 
hypotheses tested in this study. The p-value indicates there is a statistically significant 
difference between the groups in some hypotheses tested, however, we argue although 
different, both groups were still poor in the outcome measured and hence the null 
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hypothesis held true in all seven. The present study has several limitations. The 
characteristics of the responding GMPs may not fully reflect the knowledge and practices 
of all GMPs in Australia, particularly given that the response rate was 27% and the only 
district sampled was North Brisbane. Similarly, the characteristics of the responding GMSs 
entering the workforce at two large metropolitan hospitals in Brisbane may not reflect the 
variance in medical school curriculums across Australia or the knowledge and practices of 
all GMSs across Australia. 
 
4.7 Conclusion 
The present study demonstrated that Australian GMPs and GMSs had an inadequate level 
of knowledge of oral cancer, OPMLs, and risk factors, as well as skill in performing 
opportunistic oral cancer screening examinations. Although oral cancer is relatively 
uncommon in Australia, oral cancer patients often present to GMPs multiple times a year 
in the asymptomatic phase prior to their diagnosis. This suggests an opportunity for early-
stage diagnosis via opportunistic screening of high-risk individuals in the primary medical 
healthcare setting in Australia. Early-stage diagnosis is achievable and has significant 
morbidity and survival benefits for patients with oral cancer.  
 
For rates of opportunistic oral cancer screening by Australian GMPs to increase, 
interventions need to improve the knowledge and confidence of both GMSs and GMPs 
toward oral cancer and screening of high-risk individuals. Improvements to undergraduate 
medical school curriculums, development of CME programmes, and review of the 
postgraduate training curriculum of GMPs are suggested. Engagement with the RACGP in 
Australia is suggested in order to influence the content of the oral cancer prevention 
section in the next edition of RACGP published guidelines for preventive activities in 
general practice. 
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CHAPTER FIVE: GENERAL DISCUSSION AND CONCLUSION 
 
5.1 Introduction 
Most oral cancers lack early symptoms that would prompt a patient to seek diagnosis; 
hence, at presentation most patients are diagnosed with stage III or IV advanced disease. 
Prevention and early stage of diagnosis are promising for oral cancers because of known 
risk factors and the relative ease of identifying oral cancers and OPMLs by a simple oral 
cancer screening examination. However, due to the relatively low prevalence of oral 
cancer in developed communities, evidence is currently insufficient to support population-
based screening. There is significant evidence that the recommended visual and tactile 
opportunistic oral cancer screening examination, performed by trained health practitioners 
on the general and high-risk populations when asymptomatic, detects many OPMLs and 
some early-stage (Stage I) oral cancers.32, 150, 151 A large volume of evidence also links 
early stage of disease at diagnosis with significantly reduced morbidity and mortality.11, 14, 
15, 18, 19, 21, 22, 25 Together, these two bodies of evidence suggest that diagnosis in the 
asymptomatic phase via evidence-based screening initiatives is likely to have a significant 
impact on mortality and morbidity from oral cancer. Therefore, early detection of oral 
cancer and OPMLs in the asymptomatic phase via an opportunistic screening examination 
is important. It is unlikely that there will ever be a rigorously designed and implemented, 
randomly controlled trial with long-term follow-up that will prove this connection in oral 
cancer without questions of lead-time and length-time bias. Adoption of opportunistic 
screening will only be effective if patients access it and it is offered in the primary 
healthcare setting or via novel public health initiatives. The core objective of this thesis is 
to determine whether asymptomatic diagnosis of oral cancer at an early stage of disease 
is achievable in Australia, particularly in the primary medical healthcare setting. We 
achieve this by evaluating the awareness of, and attitudes toward, oral cancer and 
opportunistic screening held by recently-diagnosed oral cancer patients, experienced 
general medical practitioners, and recently-graduated medical students.  
 
5.2 Oral Cancer Patients 
This thesis evaluated an Australian cohort of patients with newly diagnosed oral cancer, 
presenting to a public hospital head and neck clinic, to identify opportunities for increasing 
early diagnosis of oral cancer. Particular emphasis was placed on investigating patient 
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interactions with GMPs and GDPs in the asymptomatic phase where the oral cancer may 
be present and detected at an earlier stage of disease.32 
 
Unfortunately, this study reports one of the lowest scores in the literature regarding 
awareness of oral cancer, with 46% stating they had never heard of oral cancer until their 
diagnosis. This alarming lack of awareness is even more concerning when added to the 
fact that 67% of participants reported being regular consumers of tobacco in Australia, 
where plain packaging of tobacco products contains graphic images of lip, mouth, tongue 
and lung cancer, and has done so for many years preceding our research. At least 67% of 
our participants should have seen oral cancer on this packaging at some point and 
reported such. Perhaps also our questionnaire should have used the term mouth or throat 
cancer as interchangeable with oral cancer and the reported awareness might not have 
been so low. Studies from the USA report that only 14-15.5% of adults had never heard of 
oral cancer.190, 191 Another Australian study investigated 101 patients referred with a 
suspicious oral lesion to a private oral medicine clinic.187 These patients reported being far 
more aware of oral cancer, with 91.8% having heard about oral cancer.187 Of interest is 
that private patients in this private oral medicine clinic expected that both GDPs and GMPs 
should check for and be able to explain oral mucosal pathology, raising the question of 
whether the general public might expect similar standards of care.187 The demographics of 
these two Australian cohorts are very different, making comparison between the two 
groups difficult; however, there is an obvious wide divide in awareness of oral cancer when 
private and public patients are compared. 
 
With regard to actual risk factors for oral cancer, this Australian cohort is consistent with 
results reported from other cohorts from developed nations, in that the most significant risk 
factors identified are increased age, tobacco use, and alcohol consumption.28, 29 95% were 
over 40 years of age at diagnosis, and 67% and 66% were regular consumers of tobacco 
and alcohol, respectively. There was poor knowledge of these important risk factors and 
almost no knowledge of HPV as a risk factor. A recent international large pooled study 
estimated the population attributable risks for tobacco and alcohol use to be 64% (95% CI: 
45-75%), showing that these two risk factors alone are responsible for a large number of 
cases.28 The poor knowledge of risk factors for oral cancer logically follows from the 
cohort’s generally poor awareness of oral cancer. Another recent Australian study, the 
Lesion Evaluation, Screening and Identification of Oral Neoplasia Study (LESIONS), has 
aimed to understand factors that may influence all oral mucosal disease in high-risk 
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populations, with a particular focus on oral cancers and OPMLs.151 LESIONS targeted two 
Australian communities at high risk of oral cancer and OPMLs, mostly in the dental 
healthcare setting but also at indigenous health clinics and a community pharmacy 
location.151 The authors have reported on the recruitment and initial screening outcomes of 
1498 participants and they confirm that those participants with higher disadvantage were 
more likely to have a history of tobacco use, as expected from international studies.151 
Those participants with low income also had significantly higher prevalence ratios of 
having suspicious oral mucosal lesions.151 Although the exact numbers were not captured, 
the authors noted a high rate of patient refusal when approached opportunistically before 
or after scheduled dental appointments.151 Common patient barriers identified in LESIONS 
were: perceived time pressure, embarrassment regarding the condition of the dentition 
(when screening attempted at community pharmacy), unwillingness to know if disease was 
detected, lack of concern and lack of pain.151 Another study investigating barriers to oral 
cancer screening in rural African-Americans showed three primary patient barriers to 
screening — lack of knowledge of oral cancer and its symptoms accounted for 31.8% of all 
barriers mentioned, lack of financial resources or health insurance for 25.0%, and fear of 
screening and diagnosis for 22.9%.133 Howell et al. (2013) placed these barriers within the 
Theory of Planned Behaviour and concluded that interventions aimed at increasing oral 
cancer screening should first focus on changing people's attitudes about screening by 
increasing knowledge about oral cancer and reducing fear.133 
 
Awareness and knowledge of oral cancer are key for patients to accept an invitation for 
oral cancer screening. This is most notable in the recently published data from Far Eastern 
Memorial Hospital in Taipei, Taiwan. Utilising a novel approach, high-risk patients 
attending an outpatient facility were identified using an automated system based on their 
responses to questions regarding tobacco and betel nut usage.32 They were then offered 
the opportunity to be screened with a standard visual and tactile oral cancer screening 
examination.32 A total of 38 693 patients were identified as high-risk, yet only 8037 (20.8%) 
were recruited as participants in the screened cohort from the automated system.32 This 
means that approximately 80% were advised that they were at high risk for developing oral 
cancer yet declined a free oral cancer screening examination. Not only do the high-risk 
populations decline screening invitations, in addition, UK research reports that the target 
high-risk population for opportunistic screening activities was shown to require further 
persuasion that their lifestyle choices (tobacco and alcohol) contributed to an increased 
risk of oral cancer.153  
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This thesis also identifies whether participants had opportunities in the Australian health 
system to receive an opportunistic oral cancer screen examination in the asymptomatic 
phase. Research has shown that patients with oral lesions often consult their GMP rather 
than their GDP, even in the UK where there is greater access to free dental treatment.156, 
157 The preference for presentation to GMPs has held true in this study, with 80% having 
seen a GMP within the last six months and 63% seeing their own regular GMP at least 
three times a year. In contrast, only 35% had seen a GDP within the last six months and 
only 6.8% visited their own regular GDP at least three times a year. While less than half of 
patients have their own regular GDP, 84% have their own regular GMP. Unfortunately, 
only 3% of these patients reported that their regular GMPs had ever discussed their risk 
factors for oral cancer, and only 6% had ever received an oral cancer screening 
examination from them. These results present an opportunity to target new education 
interventions to GMPs toward increasing opportunistic oral cancer screening in the primary 
medical healthcare setting.  
 
The evidence suggests that GDPs are more skilled and confident in performing the oral 
cancer screening examination than their medical counterparts.168, 170-173 Our study reported 
that only 47% of participants had a regular GDP, and most only attended once or twice per 
year. The remaining 53% did not have a regular GDP, and predominantly only saw a 
dentist for an emergent dental problem; therefore the average rate of dental visits in this 
group was reported as zero times per year for the vast majority. This low attendance rate 
to GDPs in Australia suggests that targeting education interventions toward increasing oral 
cancer screening with GDPs would be less productive than that with GMPs, where the 
target population is more likely to attend. A recent systematic review of patient acceptance 
of screening for oral cancer outside the dental setting showed that GMPs should be 
confident that acceptance of, and satisfaction with, oral cancer screening is high, 
particularly when patients have previously been educated about oral cancer in the waiting 
room.158 In short, the results clearly show that participants had many opportunities in the 
Australian health system to receive an opportunistic oral cancer screening examination 
before their diagnosis. Asymptomatic diagnosis of early-stage disease is certainly possible 
in the primary medical setting in Australia, dependent on knowledge and awareness of 
both patients and GMPs. 
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5.3 General Medical Practitioners 
The importance of GMP awareness of oral cancer, knowledge of the risk factors, ability to 
competently perform a visual and tactile oral cancer screening examination, and 
confidence in identifying pathology during that examination should not be underestimated. 
In our study of GMPs, only 6% reported routinely performing oral cancer screening. 
However, when asked if they do so for a high-risk patient, over 40% stated they would 
perform oral cancer screening, suggesting some awareness of high-risk populations and a 
willingness and ability to perform the screening examination in the primary medical 
healthcare setting. Initially about one-third of GMPs reported that they had sufficient 
training, knowledge, and technique to perform oral cancer screening. However, once the 
nine steps of the screening examination were shown in the next part of the questionnaire, 
only 20% of GMPs felt they had sufficient training to identify a high-risk patient and 
perform a thorough opportunistic nine-step screening examination.  
 
Similarly, knowledge of risk factors for oral cancer was also poor amongst our cohort of 
GMPs. The cohort strongly identified tobacco as a risk factor, consistent with studies from 
both developed and developing countries.168, 176, 195-197 Only 57% of GMPs identified 
alcohol as a risk factor, again consistent with other GMP studies reporting a less well-
known association of oral cancer with alcohol consumption.198 Other known risk factors, 
such as age, HPV, betel nuts, and poor diet, were not identified strongly. This deficiency in 
knowledge of risk factors for oral cancer displayed by our cohort of Australian GMPs is 
likely to limit their ability to identify high-risk patients and perform opportunistic screening. 
 
We also investigated if GMPs perform each of the nine steps of the visual and tactile oral 
cancer screening examination specified by the WHO and NIDCR.30 GMPs performed on 
average 4.3 steps of the required nine-step screening examination. Of most concern is 
that common sites of oral cancer development, such as the floor of the mouth, 
venterolateral surface of the tongue, and retromolar trigone were often overlooked. Overall 
the results of our study clearly indicate that Australian GMPs lack the awareness, 
knowledge, equipment, and skills to adequately perform opportunistic screening for oral 
cancer in high-risk patients attending their practice. These results are similar to those 
reported in studies from other developed nations. GMPs have low suspicion of oral cancer, 
are unlikely to examine patient’s oral mucosa routinely, are unlikely to advise patients 
about risk factors for oral cancer, and are likely to identify few risk factors; they lack 
knowledge regarding the main locations of oral cancer, are technically poor at performing 
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the nine steps of the oral cancer screening examination, and overall are not confident in 
diagnosing OPMLs or oral cancers.131, 134-136, 168-173 The presence of patient co-morbidities 
has also been shown to result in clinicians focusing their attention on the existing 
disorders.137-139  
 
Intent of GMPs to conduct oral cancer screening has been investigated utilising the Theory 
of Planned Behaviour, and the results suggest that there is considerable potential for 
improving intention to perform oral cancer screening in the primary medical healthcare 
setting.174 Suggested interventions include: 1) theory-based interventions, such as further 
training to enhance confidence, expertise, knowledge, and ease of examination, 2) 
provision of adequate equipment in the surgery (light and dental mirrors), and 3) 
introducing guidelines on opportunistic screening that increase motivation to comply with 
goals, such as more peers performing screening or an oral cancer awareness month.174 At 
present the RACGP teaches that there is insufficient evidence to recommend screening by 
visual inspection or by other screening methods.175  The RACGP identifies increased-risk 
individuals as smokers aged greater than 50 years, heavy drinkers, patients chewing 
tobacco or areca/betel nuts, and those exposed to excessive UV in the lip area.175  If an 
individual is identified as increased risk, the RACGP encourages opportunistic examination 
of mouth and lips every 12 months but does not provide an examination description 
matching the desired nine-step visual and tactile oral cancer screening examination.30, 175  
 
Over 50% of GMPs in this study reported that they were not confident in diagnosing 
OPMLs or oral cancer from clinical appearance. There is a statistically significant 
association between undergraduate and postgraduate teaching on examination of the oral 
cavity and whether practitioners felt confident in their ability to detect oral cancer.173 The 
key message is that any oral lesion lasting longer than 2 weeks, after local possible 
causative factors are removed, should be biopsied or referred without delay.199 The level 
of knowledge of GMPs needs to be addressed with appropriate initiatives at both the 
undergraduate and graduate levels via continued medical education (CME).173 Engaging 
with GMP training colleges, such as the RACGP in Australia, may be of benefit for review 
of the postgraduate training curriculum and updating of guidelines regarding prevention 
and early detection of oral cancer. 
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5.4 Medical Student Education 
A GMS entering the health workforce should be aware, knowledgeable, and confident in 
identifying a high-risk individual, and suggesting and performing an opportunistic oral 
cancer screening examination. Overall, the GMS results were mostly equivocal, but also 
sometimes statistically significantly worse than their more experienced GMP counterparts 
studied. In our study, 88% of GMS were not confident in diagnosing OPMLs and oral 
cancer from clinic appearance. These results were echoed by a comparison of UK 
undergraduate medical and dental students, which suggests that there will be no 
improvement in the next generation of health professionals, particularly medical 
practitioners, regarding oral cancer screening.176 Other studies in Iran, Nigeria, and the 
USA indicate a need to review the curriculum of medical and dental schools to improve 
awareness and behaviour toward increasing opportunistic oral cancer screening.177-181 In 
2011, two significant studies investigated medical school curricula for oral cancer teaching 
in the USA and UK, respectively. The majority of the responding USA medical schools 
offered very little oral health education, with approximately 80% offering less than five 
hours of oral health curriculum over the entire course.182 Oral cancer training at medical 
schools lacked both adequacy and comprehensiveness, and showed no improvement 
relative to a similar study from 15 years earlier.182, 183 The UK study highlighted that 
undergraduate oral cancer teaching varied widely in terms of duration, format, and content 
across British medical schools.184 Our GMS results point to a need to develop an 
undergraduate curriculum to address the important aspects of oral cancer from an 
evidence-based approach that can be integrated into the already crowded undergraduate 
medical curriculum.184 The question of what is being taught at medical schools across 
Australia in relation to oral cancer also remains.   
 
5.5 Opportunistic Oral Cancer Screening 
A Cochrane systematic review evaluated screening strategies for reducing oral cancer 
mortality and revealed that there was insufficient evidence to recommend inclusion or 
exclusion of screening for oral cancer using a visual and tactile examination in the general 
population, as the only significant RCT was on a high prevalence oral cancer population 
and the study was assessed as having bias in the study design.25, 27 According to the 
WHO and NIDCR, an oral cancer screening examination should include a visual 
examination of the face, neck, lips, labial mucosa, buccal mucosa, gingiva, floor of the 
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mouth, tongue, and palate with mouth mirrors to help visualise all surfaces.30 The tactile 
examination includes palpating the regional lymph nodes, tongue, and floor of the mouth.30 
The Cochrane review concluded by encouraging opportunistic screening and stating that 
GMPs and GDPs should continue to carry out visual and tactile examination of the oral 
cavity as an integral part of their routine daily work, and particular attention should be paid 
to high-risk individuals.27 Since publication of the Cochrane review in 2013, three 
significant articles have been published that further support their conclusion that 
opportunistic screening for oral cancer is important. 
 
In Asia, the emphasis is on addressing the relatively high prevalence rate of oral cancer 
due to tobacco and betel nut consumption.26 High-risk patients attending an outpatient 
facility at Far Eastern Memorial Hospital, Taipei, Taiwan, were identified using an 
automated system based on their response to questions regarding tobacco and betel nut 
usage, at the time of check-in to the outpatient facility.32 If they answered ‘yes’ to the risk 
factors, they were automatically offered the opportunity to be screened with a standard 
visual and tactile oral cancer screening examination.32 A total of 8037 high-risk patients 
were recruited as participants to the screened cohort from the automated system; 1664 
patients were identified with positive lesions, and 302 patients underwent a biopsy. 32 Five 
patients were diagnosed with oral cancer and 121 with dysplastic OPMLs.32 The stage of 
disease at diagnosis of this asymptomatic cohort was compared to a symptomatic cohort 
presenting to the same outpatient facility for investigation of a symptomatic oral lesion.32 
The symptomatic cohort comprised 157 patients with oral cancers and 61 with OPMLs, 
and, as expected, the automated screening programme identified earlier stages of oral 
cancers than the symptomatic cohort.32  
 
Two other studies report from developed nations where the prevalence of oral cancer is far 
less than in Taiwan. Monteiro et al. (2015) carried out separate invitational and 
opportunistic oral cancer screening interventions in the city of Oporto in Portugal. The first 
part of this study was an invitational screening programme where residents of Oporto were 
invited to attend on a designated screening day advertised via a mass media campaign 
including television, newspapers, radio, billboards and posters.150 A total of 267 
participants responded to the general invitation to attend the oral cancer screening day. 
The second part of the study was an opportunistic screening programme offered to 
consenting patients visiting for dental consultation (first appointment) in a public hospital of 
Oporto, and 460 screening examinations were performed in this dental healthcare setting. 
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In total, 727 individuals (277 males and 450 females) with a mean age of 54 years (range 
18-94) were included in the study. Twenty-two OPMLs, nine cases of lichen planus and 
two oral carcinomas were detected early, with both in stage one of the disease and both 
identified in the asymptomatic phase.150  
 
The two communities targeted by the LESIONS study in Australia were at high risk of oral 
cancer and OPMLs. The ten screening sites were within public and private dental clinics, 
indigenous health clinics and a community pharmacy.151 After a visual and tactile oral 
mucosal screening examination was completed by one of 11 trained and calibrated 
dentists or oral health therapists on 1498 participants, oral mucosal lesions were detected 
in over half the cohort examined, but only 16% were clinically nonhomogeneous and more 
likely to contain dysplasia or early malignant change.151  Although the results of biopsy and 
specialist review are not yet presented from this study, the volume of oral lesions detected 
is significant and likely to contribute to the evidence supporting opportunistic screening of 
high-risk populations.151   
 
In Western populations where betel nut usage is minimal, population-based annual or 
semi-annual screening for oral cancer is not cost-effective.23 Instead, targeting high-risk 
groups such as tobacco and alcohol consumers over 40 years of age to be 
opportunistically screened using a visual and tactile examination should be encouraged in 
the primary care setting.23 Over the last decade following the introduction of an oral cancer 
awareness week (now month) in the UK and the Oral Cancer Awareness Month in the 
USA in 2000, increasing numbers of oral cancer screening examinations have been 
performed each year.154, 155 It is still difficult to elucidate whether the high-risk target 
population are being reached, or whether the general population is gaining increased 
awareness and knowledge and becoming more accepting of screening activity. 
 
5.6 Conclusion 
This thesis has provided valuable insights into the challenge of achieving asymptomatic 
diagnosis of oral cancer in the early stage of disease in Australia. Oral cancer patients had 
poor awareness of oral cancer and knowledge of risk factors prior to diagnosis. Most oral 
cancer patients were over 40 years of age, and most consumed tobacco, alcohol, or both, 
suggesting a target population for opportunistic screening in the primary healthcare 
setting. Patient, professional, and total diagnostic delays were better than in many other 
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countries. Oral cancer patients are more likely to see a GMP multiple times a year for 
unrelated medical issues in the asymptomatic phase prior to their diagnosis, suggesting 
significant opportunities for GMPs to perform opportunistic oral cancer screening. Once 
symptomatic, oral cancer patients are still likely to seek help from a GMP. Initiation by a 
patient of a consultation with a GMP or GDP for an oral cancer screening examination 
would require that the patient have an improved awareness of oral cancer and knowledge 
of his or her personal risk factors for developing it. Future research should investigate the 
barriers to, and triggers of, attendance at healthcare appointments by the high-risk target 
population, and should consider novel ways of engaging in opportunistic oral cancer 
screening activity.  
 
The present study has highlighted significant missed opportunities for oral cancer 
screening, as the majority of patients visited their GMP regularly. Of concern is that, while 
84% of the oral cancer participants had a regular GMP, only 3% of those GMPs had ever 
discussed the risk factors for oral cancer, and only 6% of patients had an oral cancer 
screening examination performed on them by the GMP. This thesis has shown that 
Australian GMPs and GMSs have an inadequate level of knowledge of oral cancer, 
OPMLs, and risk factors, as well as an inadequate level of skill in performing opportunistic 
oral cancer screening examinations. At the present level of knowledge and confidence, it 
would be very unlikely for a GMP to conduct a thorough visual and tactile oral cancer 
screening examination even if a high-risk individual presented to his or her clinic. To 
encourage increased rates of screening nationally, the guidelines published by RACGP for 
preventative activities in general practice need updating in line with the latest literature and 
systematic reviews regarding opportunistic oral cancer screening. For opportunistic oral 
cancer screening activity to increase on the part of Australian GMPs, interventions are 
needed to improve the knowledge and confidence of GMPs and GMSs toward diagnosing 
oral cancer, OPMLs, and the screening of high-risk individuals. 
 
The following are recommendations for further research and interventions focused on the 
primary medical healthcare setting, identified during the thesis preparation and aimed at 
increasing the detection of asymptomatic, early-stage oral cancers and, ultimately, the 
survival of patients diagnosed with oral cancer. 
 
• Investigate the undergraduate and postgraduate medical school curricula in 
Australian Medical Schools to establish the current scope of oral medicine and 
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pathology training and ensure that the teaching incorporates reaching competency 
in risk factors for oral cancer, diagnostic confidence, and performance of the nine-
step visual and tactile examination for oral cancer screening. 
• Engage the RACGP to reconsider the evidence for opportunistic screening and 
modify the current guidelines for preventative activities in general practice. 
• Investigate the most effective ways of training GMPs and ensure that teaching 
incorporates reaching competency in risk factors for oral cancer, diagnostic 
confidence, and performance of the nine-step visual and tactile oral cancer 
screening examination. 
• Investigate the most effective ways of raising awareness among the general public 
of oral cancer, its risk factors, and the availability of screening examinations at 
GMPs or GDPs. 
• Investigate the most effective ways of raising awareness among the high-risk target 
population of oral cancer, its risk factors, and the availability of screening 
examinations at GMPs or GDPs. 
• Investigate the roles that professional organisations – such as the Australian 
Medical Association, Australian Dental Association, Oral Medicine and Oral 
Pathology Societies, and Australian and New Zealand Head and Neck Cancer 
Societies – are taking in public awareness campaigns, health practitioner education 
interventions, and policy development to improve early detection of oral cancer. 
• Engage the Preventative Health Taskforce with submissions at any future 
opportunity to include early detection of oral cancer as part of future updates or 
revisions to the Australian National Preventative Health Strategy. 
 
Asymptomatic diagnosis of oral cancer in the early stage of disease is achievable in the 
primary medical healthcare setting in Australia. The present study and literature review 
shows that it has already been achieved in the primary dental healthcare setting in 
Australia, and lessons in undergraduate and postgraduate training can be taken from the 
Australian dental profession. Changing the ingrained practice behaviour of the Australian 
GMP population toward opportunistic oral cancer screening is a great challenge that will 
require determined effort both from individuals and from professional multi-disciplinary 
societies, such as the Australian and New Zealand Head and Neck Cancer Society. The 
rigorous design and implementation of further research activities following the above 
recommendations will enhance the early detection of oral cancer.   
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Appendix A: Participant with Oral Cancer Questionnaire 
Participant Questionnaire  
 
This	  questionnaire	  has	  been	  designed	  with	  the	  purpose	  of	  using	  the	  information	  obtained	  to	  consider	  ways	  
of	  improving	  prevention,	  early	  detection	  and	  referral	  of	  oral	  cancer	  from	  both	  general	  medical	  and	  dental	  
practitioners.	  
	  
The	  information	  you	  provide	  will	  likely	  guide	  efforts	  to	  increase	  awareness	  of	  oral	  cancer	  and	  early	  
detection	  of	  it	  throughout	  Australia.	  
	  
Age:…..……yrs	   Sex:	  	  Male/Female	   	  
___________________________________________________________________________	  
	  
Before	  you	  were	  diagnosed	  did	  you	  have	  any	  experience	  with	  oral	  cancer?	  
(Please	  answer	  all	  questions)	  
Have	  you	  worked	  with	  patients	  with	  oral	  cancer	  in	  a	  health	  care	  role?	  	  YES	  or	  NO	  	  	  
If	  Yes,	  What	  role?...................................	  
Have	  you	  had	  a	  previous	  diagnosis	  of	  oral	  cancer	  in	  your	  mouth?	  	  YES	  or	  NO	  
Have	  you	  had	  a	  previous	  diagnosis	  of	  oral	  cancer	  in	  your	  extended	  family?	  YES	  or	  NO	  
Have	  you	  had	  a	  previous	  diagnosis	  or	  oral	  cancer	  in	  a	  friend?	  YES	  or	  NO	  
Have	  you	  heard	  of	  a	  previous	  diagnosis	  of	  oral	  cancer	  in	  someone	  not	  known	  to	  you	  but	  you	  had	  heard	  
about	  it	  from	  others	  talking	  or	  online?	  YES	  or	  NO	  
Have	  you	  ever	  read	  anything	  about	  oral	  cancer	  prior	  to	  your	  diagnosis?	  YES	  or	  NO	  
Had	  you	  never	  heard	  of	  oral	  cancer	  at	  all	  until	  you	  were	  diagnosed?	  	  YES	  or	  NO	  
	  
Before	  you	  were	  diagnosed	  what	  was	  your	  knowledge	  of	  any	  risk	  factors	  that	  could	  increase	  your	  
chances	  of	  oral	  cancer?	  
(List	  as	  many	  as	  you	  were	  aware	  of	  before	  diagnosis)	  
……………………………………………………………………………………………………………………………………	  
	  
Were	  you	  diagnosed	  before	  you	  developed	  symptoms?	  	  YES	  or	  NO	  
	  
If	  Yes,	  who	  examined	  you	  to	  diagnose	  the	  cancer?	  
(circle	  best	  option)	  
a)	  Doctor	  (GP)	  	  or	  	  b)	  Doctor	  (Specialist)	  -­‐	  please	  specify?..................................................	  
c)	  Public	  Hospital	  Emergency	  Department	  Doctor	  
d)	  Dentist	  (GP)	  or	  	  e)	  Dentist	  (Specialist)	  –	  please	  specify?................................................	  
f)	  Other	  Health	  Practitioner	  –	  please	  specify?...........................................................................	  
	  
Did	  you	  develop	  symptoms	  before	  diagnosis?	  	  YES	  or	  NO	  
	  
If	  Yes,	  what	  symptoms	  did	  you	  develop?	  
(List	  as	  many	  as	  you	  were	  aware	  of	  before	  diagnosis)	  
……………………………………………………………………………………………………………………………………	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When	  did	  you	  first	  become	  aware	  of	  symptoms:	  	  ____	  /	  ____	  /	  _____	  
(at	  least	  month	  and	  year)	  
	  
What	  type	  of	  health	  care	  professional	  did	  you	  choose	  to	  attend	  first	  to	  assist	  you	  with	  diagnosing	  the	  
cause	  of	  your	  symptoms?	  
(circle	  best	  option)	  
a)	  Doctor	  (GP)	  	  or	  	  b)	  Doctor	  (Specialist)	  -­‐	  please	  specify?..................................................	  
c)	  Public	  Hospital	  Emergency	  Department	  Doctor	  
d)	  Dentist	  (GP)	  or	  	  e)	  Dentist	  (Specialist)	  –	  please	  specify?................................................	  
f)	  Other	  Health	  Practitioner	  –	  please	  specify?...........................................................................	  
	  
When	  did	  you	  first	  attend	  this	  health	  professional	  once	  you	  were	  concerned	  about	  your	  symptoms:	  	  
______	  /	  ______	  /	  _______	  
(at	  least	  month	  and	  year)	  
	  
Date	  of	  first	  attendance	  at	  Head	  and	  Neck	  Clinic:	  ______	  /	  ______	  /	  _______	  
	  
	  
Now	  think	  back	  to	  the	  period	  prior	  to	  your	  symptoms	  before	  answering	  the	  next	  section	  of	  questions.	  
Use	  the	  date	  at	  the	  top	  of	  this	  page	  as	  your	  reference.	  
	  
Did	  you	  access	  a	  General	  Medical	  Practitioner	  (GP)	  in	  Australia	  prior	  to	  this	  date	  in	  the	  preceding	  two	  
years	  for	  any	  other	  reason	  (i.e.	  other	  illness,	  prescriptions,	  medical	  check-­‐up,	  certificate	  etc.)?	  	  	  YES	  or	  NO	  
When	  was	  the	  last	  visit	  to	  the	  General	  Medical	  Practitioner	  (GP)	  	  
(circle	  best	  answer)	  
a)	  less	  than	  one	  month	  before	  symptoms	  
b)	  between	  one	  and	  three	  months	  before	  symptoms	  
c)	  between	  three	  and	  six	  months	  before	  symptoms	  
d)	  six	  to	  twelve	  months	  before	  symptoms	  
e)	  greater	  than	  twelve	  months	  before	  symptoms	  
Do	  you	  have	  a	  regular	  GP	  in	  Australia	  that	  you	  would	  call	  “your	  GP”?	  	  YES	  or	  NO	  
If	  Yes,	  how	  often	  in	  a	  year	  would	  you	  roughly	  see	  “your	  GP”	  ?	  
a)	  zero	  	  	  b)	  once	  	  c)	  twice	  	  d)	  three	  	  e)	  four	  	  f)	  more	  than	  four	  	  
If	  No,	  how	  often	  in	  a	  year	  would	  you	  seek	  medical	  advice	  from	  any	  GP?	  
a)	  zero	  	  	  b)	  once	  	  c)	  twice	  	  d)	  three	  	  e)	  four	  	  f)	  more	  than	  four	  	  
At	  any	  time	  in	  your	  life	  has	  any	  GP	  you	  attended	  in	  Australia	  ever	  discussed	  oral	  cancer	  with	  you	  or	  the	  
risk	  factors	  you	  may	  have	  for	  oral	  cancer?	  YES	  or	  NO	  
Whilst	  it	  is	  not	  standard	  of	  care	  in	  Australia	  to	  have	  an	  oral	  cancer	  screen	  regularly,	  we	  are	  interested	  if	  
can	  you	  recall	  at	  any	  time	  in	  your	  life	  if	  any	  GP	  in	  Australia	  ever	  performed	  an	  oral	  cancer	  screening	  
examination	  on	  you?	  YES	  or	  NO	  
	  (An	  oral	  cancer	  screening	  examination	  involves	  feeling	  your	  face	  and	  neck	  for	  lymph	  nodes	  while	  doctor	  
stands	  behind	  you,	  in	  addition	  to	  looking	  at	  the	  inside	  of	  your	  lips,	  around	  your	  teeth	  left	  and	  right	  with	  a	  
dental	  mirror,	  up	  on	  your	  palate,	  top	  of	  tongue,	  under	  tongue	  and	  down	  both	  sides	  of	  the	  tongue,	  and	  
finally	  the	  throat.	  You	  need	  a	  dental	  mirror	  and	  a	  light	  to	  do	  this	  and	  takes	  about	  2-­‐5minutes	  to	  complete.)	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Did	  you	  access	  a	  General	  Dental	  Practitioner	  (Dentist)	  in	  Australia	  prior	  to	  this	  date	  in	  the	  preceding	  two	  
years	  for	  any	  other	  reason	  (i.e.	  other	  oral	  illness	  or	  dental	  check-­‐up	  etc.)?	  	  	  YES	  or	  NO	  
	  
When	  was	  the	  last	  visit	  to	  the	  General	  Dental	  Practitioner	  (Dentist)?	  	  
(circle	  best	  answer)	  
a)	  less	  than	  one	  month	  before	  symptoms	  
b)	  between	  one	  and	  three	  months	  before	  symptoms	  
c)	  between	  three	  and	  six	  months	  before	  symptoms	  
d)	  six	  to	  twelve	  months	  before	  symptoms	  
e)	  greater	  than	  twelve	  months	  before	  symptoms	  
	  
Do	  you	  have	  a	  regular	  dentist	  that	  you	  would	  call	  “your	  dentist”?	  	  YES	  or	  NO	  
If	  Yes,	  how	  often	  in	  a	  year	  would	  you	  roughly	  see	  “your	  dentist”	  ?	  
a)	  zero	  	  	  b)	  once	  	  c)	  twice	  	  d)	  three	  	  e)	  four	  	  f)	  more	  than	  four	  	  
If	  No,	  how	  often	  in	  a	  year	  would	  you	  seek	  a	  dental	  review	  from	  a	  dentist?	  
a)	  zero	  	  	  b)	  once	  	  c)	  twice	  	  d)	  three	  	  e)	  four	  	  f)	  more	  than	  four	  	  
	  
	  At	  any	  time	  in	  your	  life	  has	  any	  Dentist	  you	  attended	  in	  Australia	  ever	  discussed	  oral	  cancer	  with	  you	  or	  
the	  risk	  factors	  you	  may	  have	  for	  oral	  cancer?	  YES	  or	  NO	  
	  
At	  any	  time	  in	  your	  life	  has	  any	  Dentist	  in	  Australia	  ever	  performed	  an	  oral	  cancer	  screen	  on	  you?	  
(This	  involves	  feeling	  your	  face	  and	  neck	  for	  lymph	  nodes	  in	  addition	  to	  looking	  at	  the	  inside	  of	  your	  lips,	  
around	  your	  teeth,	  on	  your	  palate,	  tongue,	  under	  tongue	  and	  down	  both	  sides	  of	  the	  tongue,	  and	  finally	  
the	  throat.	  You	  need	  a	  dental	  mirror	  and	  a	  light	  to	  do	  this)	  
YES	  or	  NO	  
	  
Please	  confirm	  if	  you	  had	  any	  of	  these	  known	  risk	  factors	  prior	  to	  symptoms	  developing	  in	  your	  
individual	  situation?	  (circle	  as	  many	  as	  are	  applicable	  to	  you)	  
a)	  Age	  over	  40	  years	   b)	  Alcohol	  consumption	  	   c)	  Human	  Papilloma	  Virus	  (HPV)	  
d)	  Tobacco	  Consumption	  (chewing,	  smoking	  and	  passive)	  	   e)	  Chewing	  betel	  quid	  (nut)	  
f)	  Diet	  low	  in	  fresh	  fruit	  and	  vegetables	  
	  
Finally	  is	  there	  any	  other	  health	  professional	  who	  has	  performed	  an	  oral	  cancer	  screen	  on	  you	  in	  
Australia?	  YES	  or	  NO	  	  	  If	  Yes,	  please	  specify	  what	  type	  of	  professional?	  ____________	  
	  
-­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  -­‐	  	  
This	  section	  will	  be	  detached	  from	  your	  survey	  so	  as	  to	  de-­‐identify	  your	  responses	  and	  maintain	  your	  
privacy.	  However	  prior	  to	  this	  occurring	  the	  principal	  investigator,	  Dr	  John	  Webster	  may	  need	  to	  contact	  
you	  to	  clarify	  responses	  so	  please	  provide	  your	  contact	  details	  below	  if	  you	  consent	  to	  being	  contacted	  for	  
clarification	  purposes.	  	  
	  
NAME:	  ______________________________________	  PHONE:	  ________________________	  
	  
ADDRESS:	  ___________________________________________________________________	  
	  
EMAIL	  ADDRESS:	  _____________________________________________________________ 
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Appendix B: General Medical Practitioner Participant Questionnaire 
General Medical Practitioner Participant Questionnaire 
 
 
Age:…..……yrs Sex:  Male/Female  
 
Graduating Year of Medical School:……………… 
 
Qualifications:………………………………………………. 
_______________________________________________________________________________________ 
 
Do you perform oral cancer screening routinely?    YES or NO 
 
If you answered no to the above question, do you perform oral cancer screening if the patients are in 
high risk categories?      YES or NO 
 
What would you consider risk factors for oral cancer? 
(list as many as you can recall) 
………………………………………………………………………………………………………………… 
………………………………………………………………………………………………………………… 
Do you regularly advise patients about risk factors for oral cancer?  
YES or NO 
 
Do you regularly advise patients about risks factors for other cancers?   
YES or NO 
 
Do you regularly encourage reduction in risk factors for cancers? 
YES or NO 
 
In regards to clinical appearance do you feel confident diagnosing oral cancer or pre-malignant oral 
lesions from clinical appearance? 
 
Very confident Confident Unsure Very Unsure  
 
What changes in the mouth would you associate with pre-malignancy? 
………………………………………………………………………………………………………………… 
………………………………………………………………………………………………………………… 
 
What changes in the mouth would you associate with oral cancer? 
………………………………………………………………………………………………………………… 
………………………………………………………………………………………………………………… 
 
Do you have sufficient training, knowledge and technique to perform and oral cancer screening 
examination?   YES or NO 
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 Do you have all the tools required to perform an oral cancer screening? 
a) A source of bright white light?   YES or NO 
b) A dental or ENT mirror?   YES or NO 
c) Access to gauze squares?   YES or NO  
 
Step 1: Extra-oral examination 
Palpate the face and neck to exclude lymphadenopathy and lesions. 
 
Do you perform this step in your routine? 
 
YES or NO 
 
 
 
How confident are you with your technique of extra-oral examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology in extra-oral examination? 
Very confident Confident Unsure Very Unsure   
 
 
Step 2: Lip Examination 
Note colour, texture and surface changes and changes at vermillion 
borders. 
 
Do you perform this step in your routine? 
 
YES or NO 
 
 
How confident are you with your technique of lip examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology in lip examination? 
Very confident Confident Unsure Very Unsure   
 
Step 3: Labial Mucosa Examination 
Note colour, texture and any swelling or other abnormalities in 
vestibular mucosa and gingiva. 
 
Do you perform this step in your routine? 
 
YES or NO 
 
 
 
 
How confident are you with your technique of labial mucosa examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the labial mucosa? 
Very confident Confident Unsure Very Unsure   
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Step 4: Buccal Mucosa Examination 
Using dental/ENT mirrors examine with bright white light the 
right and left buccal mucosa from anterior labial commissure 
back to tonsillar pillar. 
 
Do you perform this step in your routine? 
YES or NO 
 
 
 
 
How confident are you with your technique of buccal mucosa examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the buccal mucosa? 
Very confident Confident Unsure Very Unsure 
 
 
Step 5: Gingival Examination 
As in step 4 look around the oral cavity with dental mirror and 
bright white light to examine the buccal and lingual gingiva. 
 
Do you perform this step in your routine? 
 
YES or NO 
 
 
 
How confident are you with your technique of gingival examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the gingiva? 
Very confident Confident Unsure Very Unsure 
 
 
 
 Step 6: Tongue Examination 
Assess colour, texture, mobility and positioning. Grasp tip with gauze and assist full protrusion. Assess 
posterior and lateral borders with mirror while retracting cheek. Palpate the dorsum and lateral borders for 
hard tissue development. 
 
Do you perform this step in your routine?  YES or NO 
How confident are you with your technique of tongue examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the tongue? 
Very confident Confident Unsure Very Unsure 
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Step 7:  Ventral Tongue and Floor of 
Mouth 
Ask patient to lift tongue. Use gauze to 
dry floor of mouth and assess the ventral 
tongue and floor of mouth tissue for 
pathological changes. 
 
Do you perform this step in your 
routine?    YES or NO 
 
 
How confident are you with your technique of floor of mouth examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the floor of mouth? 
Very confident Confident Unsure Very Unsure 
 
 
Step 8: Palate and Oro-pharynx 
Use dental mirror to depress the tongue and bright white light 
to examine hard and soft palate and then patients says” Argh” 
to view oro-pharynx.  
 
Do you perform this step in your routine? 
YES or NO 
 
How confident are you with your technique of tongue examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the tongue? 
Very confident Confident Unsure Very Unsure 
 
 
Step 9: Bimanual palpation of Floor of Mouth 
One finger in floor of mouth and hand under chin to palpate for abnormality 
between fingers. Palpate any other pathology noticed on examination. 
 
Do you perform this step in your routine?    YES or NO 
 
How confident are you with your technique of bimanual palpation? 
Very confident       Confident       Unsure       Very Unsure 
   
How confident are you with identifying pathology using this method of 
palpation? 
Very confident       Confident       Unsure        Very Unsure 
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Where would you refer a patient if you suspected a pre-malignant lesion in the oral cavity? 
Plastic Surgeon       ENT Surgeon      Oral and Maxillofacial Surgeon     Dentist 
Oral Medicine/Oral Pathologist        Other Specialist (please specify):……………………… 
I would observe and manage myself  
 
Where would you refer a patient if you suspected an oral cancer? 
Plastic Surgeon       ENT Surgeon      Oral and Maxillofacial Surgeon     Dentist 
Oral Medicine/Oral Pathologist        Other Specialist (please specify):……………………… 
I would observe and manage myself 
 
Do you feel you have sufficient knowledge concerning prevention of oral cancer? 
YES or NO 
 
Do you feel you have sufficient knowledge to detect a pre-malignant lesion or an early asymptomatic 
oral cancer? 
YES or NO 
 
Do you feel you received sufficient training through medical school and general practice training to 
identify high risk groups and perform thorough opportunistic oral cancer screening? 
YES or NO 
 
Has anyone ever performed an oral cancer screen on yourself? 
(This could be a general medical or a dental practitioner) 
YES or NO 
 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
This	  section	  will	  be	  detached	  from	  your	  survey	  so	  as	  to	  de-­‐identify	  your	  responses	  and	  maintain	  your	  
privacy.	  However	  prior	  to	  this	  occurring	  the	  principal	  investigator,	  Dr	  John	  Webster,	  may	  need	  to	  contact	  
you	  to	  clarify	  responses	  so	  please	  provide	  your	  contact	  details	  below	  if	  you	  consent	  to	  being	  contacted	  for	  
clarification	  purposes.	  	  
	  
NAME:	  ______________________________________	  PHONE:	  ________________________	  
	  
ADDRESS:	  ___________________________________________________________________	  
	  
EMAIL	  ADDRESS:	  _____________________________________________________________ 
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Appendix C: Graduate Medical Student Participant Questionnaire 
GRADUATE MEDICAL STUDENT PARTICIPANT QUESTIONNAIRE 
 
This questionnaire has been designed with the purpose of using the information obtained to consider ways of 
improving prevention, early detection and referral of oral cancer from both general medical and dental 
practitioners. 
 
Age:…..……yrs Sex:  Male/Female  
 
Graduating Year of Medical School:……………………………………………………………… 
 
Qualifications:……………………………………………………………………………………………….. 
 
University attended for Medical School:………………………………………………………. 
 
How many years were you in attendance at Medical School:……………………….. 
_____________________________________________________________________________________________ 
 
During training did you ever see an oral cancer in a patient’s mouth?   YES or NO 
 
During training did you ever see a pre-malignant oral lesion (PMOL) in a patient’s mouth? YES or NO 
 
During training did you ever discuss or learn about oral cancer in lecture, problem-based learning, tutorial or 
have clinical exposure to a patient with oral cancer?   YES or NO 
 
During training did you ever discuss or learn about opportunistic screening for oral cancer in lecture, problem-
based learning, tutorial or during clinical experience?  YES or NO 
 
From your training do you feel you have sufficient knowledge and technique to perform an oral cancer screening 
examination? YES or NO 
 
If asked to perform an oral cancer screening examination right now, which of the following would indicate your 
confidence in performing this correctly? 
 
Very confident Confident Unsure Very Unsure  
 
In your clinical experience do you examine patients’ oral mucosa routinely? YES or NO 
 
If you answered NO to the above question, do you screen the oral mucosa if the patients are in high risk 
categories or have risk factors for oral cancer?      YES or NO 
 
What would you consider risk factors for oral cancer? 
(list as many as you can recall) 
………………………………………………………………………………………………………………………... 
………………………………………………………………………………………………………………………... 
 
Do/will you regularly advise patients about risk factors for oral cancer? YES or NO 
 
Do/will you regularly encourage risk factor reduction for oral cancer? YES or NO 
 
Do/will you regularly advise patients about risks factors for other cancers?  YES or NO 
 
Do/will you regularly encourage risk factor reduction for other cancers?  YES or NO 
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Do you feel confident diagnosing oral cancer or pre-malignant oral lesions from clinical appearance? 
 
Very confident Confident Unsure Very Unsure  
 
What changes in the mouth would you associate with pre-malignancy? 
………………………………………………………………………………………………………………………... 
………………………………………………………………………………………………………………………... 
 
What changes in the mouth would you associate with oral cancer? 
………………………………………………………………………………………………………………………... 
………………………………………………………………………………………………………………………... 
 
 
The following 8 steps are included in an oral cancer screening examination. Research also suggests a bright white 
light  (not simply a torch/pupil torch), dental/ENT mirror and gauze squares are required for adequate 
visualization of all areas during the examination. 
 
 Do you have all the tools required to perform an oral cancer screening in your workplace? 
a) A source of bright white light?   YES or NO or UNSURE 
b) A dental or ENT mirror?   YES or NO or UNSURE 
c) Access to gauze squares?   YES or NO or UNSURE  
 
 
Step 1: Extra-oral examination 
Palpate the face and neck to exclude lymphadenopathy and lesions. 
 
Do you perform this step in your routine?   
 
YES or NO 
 
 
 
How confident are you with your technique of extra-oral examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology in extra-oral examination? 
Very confident Confident Unsure Very Unsure   
 
 
Step 2: Lip Examination 
Note colour, texture and surface changes and changes at vermillion borders. 
 
Do you perform this step in your routine? 
 
YES or NO 
 
 
 
How confident are you with your technique of lip examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology in lip examination? 
Very confident Confident Unsure Very Unsure   
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Step 3: Labial Mucosa Examination 
Note colour, texture and any swelling or other abnormalities in 
vestibular mucosa and gingiva. 
 
Do you perform this step in your routine? 
 
YES or NO 
 
 
 
 
 
How confident are you with your technique of labial mucosa examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the labial mucosa? 
Very confident Confident Unsure Very Unsure   
  
 
Step 4: Buccal Mucosa Examination 
Using dental/ENT mirrors examine with bright white light the right 
and left buccal mucosa from anterior labial commissure back to 
tonsillar pillar. 
 
Do you perform this step in your routine? 
 
YES or NO 
 
 
 
 
How confident are you with your technique of buccal mucosa examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the buccal mucosa? 
Very confident Confident Unsure Very Unsure 
 
Step 5: Gingival Examination 
As in step 4, look around the oral cavity with dental mirror and bright 
white light to examine the buccal and lingual gingiva. 
 
Do you perform this step in your routine? 
 
YES or NO 
 
 
 
 
How confident are you with your technique of gingival examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the gingiva? 
Very confident Confident Unsure Very Unsure 
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 Step 6: Tongue Examination 
Assess colour, texture, mobility and positioning. Grasp tip with gauze and assist full protrusion. Assess posterior and 
lateral borders with mirror while retracting cheek. Palpate the dorsum and lateral borders for hard tissue development. 
 
Do you perform this step in your routine?  YES or NO 
 
How confident are you with your technique of tongue examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the tongue? 
Very confident Confident Unsure Very Unsure 
 
 
Step 7:  Ventral Tongue and Floor of Mouth 
Ask patient to lift tongue. Use gauze to dry floor of 
mouth and assess the ventral tongue and floor of mouth 
tissue for pathological changes. 
 
Do you perform this step in your routine?     
 
YES or NO 
 
 
How confident are you with your technique of floor of mouth examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the floor of mouth? 
Very confident Confident Unsure Very Unsure 
 
 
 
Step 8: Palate and Oro-pharynx 
Use dental mirror to depress the tongue and bright white light to examine 
hard and soft palate and then patients says ”Ahh” to view oro-pharynx.  
 
Do you perform this step in your routine? 
YES or NO 
 
 
 
How confident are you with your technique of tongue examination? 
Very confident Confident Unsure Very Unsure   
 
How confident are you with identifying pathology of the tongue? 
Very confident Confident Unsure Very Unsure 
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Step 9: Bimanual palpation of Floor of Mouth 
Place one finger in floor of mouth and other hand under chin to palpate for abnormality 
between fingers. Palpate any other pathology noticed on examination. 
 
Do you perform this step in your routine?    YES or NO 
 
How confident are you with your technique of bimanual palpation? 
Very confident       Confident       Unsure       Very Unsure 
   
How confident are you with identifying pathology using this method of palpation? 
Very confident       Confident       Unsure        Very Unsure 
 
 
 
 
 
 
 
Now that you are aware of all the steps, has anyone ever performed an opportunistic oral cancer screening 
examination on you? (This could be a general medical or a dental practitioner) 
 
YES or NO 
 
Where would you refer a patient if you suspected a pre-malignant oral lesion? 
Plastic Surgeon       ENT Surgeon      Oral and Maxillofacial Surgeon     Dentist 
Oral Medicine/Oral Pathologist        Other Specialist (please specify):……………………… 
I would observe and manage myself  
 
Where would you refer a patient if you suspected an oral cancer? 
Plastic Surgeon       ENT Surgeon      Oral and Maxillofacial Surgeon     Dentist 
Oral Medicine/Oral Pathologist        Other Specialist (please specify):……………………… 
I would observe and manage myself 
 
In Australia do you think a patient should go to a general medical practitioner (Doctor) or a general dental 
practitioner (Dentist) if he/she has an oral lesion? 
 
DOCTOR or DENTIST 
 
Overall do you feel you have sufficient knowledge concerning prevention of oral cancer? 
 
YES or NO 
 
Overall do you feel you have sufficient knowledge to detect a pre-malignant lesion or an early asymptomatic oral 
cancer? 
 
YES or NO 
 
Overall do you feel you received sufficient training through medical school to identify high-risk groups and 
perform thorough opportunistic oral cancer screening examinations? 
 
YES or NO 
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This	  section	  will	  be	  detached	  from	  your	  survey	  so	  as	  to	  de-­‐identify	  your	  responses	  and	  maintain	  your	  
privacy.	  However	  prior	  to	  this	  occurring	  the	  principal	  investigator,	  Dr	  John	  Webster	  may	  need	  to	  contact	  
you	  to	  clarify	  responses	  so	  please	  provide	  your	  contact	  details	  below	  if	  you	  consent	  to	  being	  contacted	  for	  
clarification	  purposes.	  	  
	  
NAME:	  ______________________________________	  PHONE:	  ________________________	  
	  
ADDRESS:	  ___________________________________________________________________	  
	  
EMAIL	  ADDRESS:	  _____________________________________________________________ 
 
 
 
 
 
